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Abstract 
Alcohol dehydrogenase inhibitors may be employed for the treatment of parasitic infection 
in humans. A series of substituted pyrazoline derivatives were synthesized to elucidate the 
pharmacophore for the inhibition of ADH. Targeted structure modification was used to 
alter the electronic and steric interactions associated with the enzyme active site. This 
study identified several effective N-aryl-carboxamide derivatives with horse liver ADH 
inhibition, comparable to that of 4-methylpyrazole, a known ADH inhibitor. The 
identification of pharmacophoric regions will allow for the methodological modification of 
these compounds to improve enzyme affinity and targeted inhibition. Future research may 
include additional solubility, toxicity and docking analysis of these compounds. 
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Chapter 1: Introduction 
1.1: Introduction 
Alcohol dehydrogenase (ADH) enzymes, present in both prokaryotes and eukaryotes, are 
responsible for alcohol metabolism and rely upon the reversible conversion between 
NADH (nicotinamide adenine dinucleotide) and NAD+ for anaerobic metabolism 
(Scheme 1). Alcohol dehydrogenases are essential for the growth and survival of many 
bacteria and eukaryotic parasites through fermentation metabolism. In humans, alcohol 
dehydrogenases are required for the breakdown of alcohol into acetaldehyde and acetate.1 
Humans possess several enzymes capable of metabolizing alcohol through oxidative  
(alcohol dehydrogenase,  cytochrome P450 isoxymes, and catalase) and non-oxidative 
pathways (fatty acid ethyl ester synthase and phospholipase D)1. As ADHs are present 
but nonessential in humans, therapeutics can be designed to inhibit anaerobic parasite 
metabolism via ethanol fermentation. 
 
Scheme 1. Interconversion between alcohol and aldehyde by alcohol dehydrogenases.  
 
Drug design relies heavily upon the identification of highly effective compounds with 
low toxicity in humans. Enzyme inhibitors are designed specifically to optimize binding 
efficiency at the active site of a target enzyme often of medicinal or therapeutic interest. 
An understanding of the enzyme active site characteristics may allow for optimization of 
cooperative interactions, thus increasing binding efficiency and enzyme inhibition. 
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Protein amino acid sequences, crystal structures, and modeling software are commonly 
used to understand likely binding interactions with target molecules. Most effective 
inhibitors will have a low inhibitory concentration (Ki)a required to significantly decrease 
function. At these low concentrations, the inhibitory compounds ought to have low 
toxicity as well. Inhibitors are commonly screened for drug properties including toxicity, 
carcinogenicity, and metabolic stability with LD50b, AMES (mutagenic potential 
determination), and LC-MS serum monitoring assays.  
 
Fomepizole, 4-methylpyrazole (Figure 1), is an effective ADH inhibitor (Ki of 0.013 μM 
for horse liver ADH)2 and subsequent structural modifications have been done to assess it 
as an anti-parasitic and anti-inflammatory agent3–5.  This compound has been used as a 
therapeutic agent for the treatment of methanol poisoning since 19973–5. 4-
Methylpyrazole exhibits an ADH binding affinity greater than 8,000 times that of ethanol 
with no significant toxicity identified at concentrations required for methanol poisoning 
treatment6. The effectiveness of this small substructure has sparked interest in other 
nitrogen heterocycles, such as pyrazolines.  
 
 
Figure 1. 4-Methylpyrazole 
 
                                                 
a The Inhibitor constant (Ki) of a compound is equal to the concentration of inhibitor that results in half 
maximal inhibition. Low Ki values are associated with effective inhibitors and stronger binding affinity.  
b The LC50 for pharmaceuticals is equivalent to the treatment dose required for death in 50% of subjects. 
This value is directly correlated with drug toxicity.  
NH N
 3
Several pyrazoline and triazole derivatives are currently under investigation as 
therapeutic agents for inflammation, tumor suppression, and parasitic infection 
management7–12. Pyrrole and pyrazoles are the structural units for many natural products, 
including withasomnine and pyrazomycin (Figure 2)10,13,14. Pyrazomycin, (pyrazofurin), 
was isolated as a fermentation product of Streptomyces candidus and has proven to be an 
extremely effective monophosphate decarboxylase inhibitor (Ki 5.0 nM)10. The diverse 
applications of these derivatives in current pharmaceutics also indicates that these may be 
effective as inhibitors for a wide range of enzyme families including monoamine 
oxidases, NADPH oxidases, ipoxygenases and cyclooxygenases15–17. 
 
  
Figure 2.  “Withasomnine” (3-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole) and 
“Pyrazomycin” ((1S)-1,4-Anhydro-1-(5-carbamoyl-4-hydroxy-1H-pyrazol-3-yl)-D-
ribitol). 
 
Pyrazoline derivatives specifically have been identified as effective anti-tubercular 
agents, which provide an alternative approach for the treatment of multi-drug resistant 
infections18.  Additionally, several 1,3-disubstituted, 1,3,4-trisubstituted, and 1,3,5-
trisubstituted pyrazolines have been identified as successful inhibitors of anaerobic 
growth in the parasitic protist Entamoeba histolytica. The mode of inhibition by these 
compounds has yet to be elucidated8,19–21.  
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The thiocarbamoyl substituent (adjacent to the pyrazoline) may potentially be the 
pharmacophore for these molecules22. Carbamates and thiocarbamates have been shown 
to provide significant anti-fungal, anti-cancer, and anti-protozoal properties22–24. 
Thiocarbamoyl derivatives have exhibited an increased efficiency, relative to carbamoyl 
derivatives for E. histolytica trophozoite growth inhibition, which relies upon ADH 
function (EhADH2) for anaerobic growth and survival25–28. It is presumed that inhibition 
of the alcohol dehydrogenase function of this bifunctional enzyme will eliminate 
trophozoite growth.  
 
The current treatment for E. histolytica infection is the antiprotozoal drug metronidazole. 
Metronidazole acts as a DNA replication inhibitor and has been proven to be effective for 
E. histolytica growth inhibition at an IC50c value of 9.5 μM (Figure 3)7,25,27. This 
treatment is associated with significant neural toxicity and morbidity. As such, alternative 
treatments are desirable. The identification of alternative treatments for parasitic and 
bacterial infections are also necessary as current treatments are toxic and drug resistance 
is increasing.  
 
 
Figure 3. “Metronidazole”, 2-methyl-5-nitroimidazole-1-ethanol.  
 
                                                 
c The IC50 value of a compound is equivalent to the concentration required to reduce substrate binding by 
50%. Low IC50 values are associated with strong competitive inhibitors.  
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As ADH is nonessential to human health, the identification of effective ADH inhibitors 
may allow for the improved treatment of several bacterial and parasitic infections25,28,29. 
Additionally, the identification of pharmacophoric regions of substituted pyrazolines may 
allow for the targeted modification of known inhibitors for improved function and more 
effective drug treatments. Therefore, this research project may be directly applied to drug 
screening and subsequent pharmaceutical development.  
 
The compounds synthesized in this study will be evaluated for their inhibitory efficiency 
in order to determine alternative therapeutic target scaffolds for the management of 
bacterial and parasitic infection. A goal of this study is to identify pyrazoline inhibitors 
with inhibition comparable to or better than that of 4-methylpyrazole. The identification 
of the potential pharmacophoric regions of substituted pyrazoline and/or pyrazole 
derivatives may then allow for further methodological modification for improved ADH 
affinity and targeted inhibition. 
 
 
Figure 4. 1,3-diaryl substituted carbamoyl pyrazoline structure. 
 
We propose to probe the carbamoyl pyrazoline structure through modification of regions 
A, B, and C (Figure 4). Rings A and C will be modified through the investigation of aryl 
substituents with varied electron donating and withdrawing properties, as well as 
modifying the aryl ring to alkyl groups. The pyrazoline heterocycle, B, will also be 
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investigated through oxidation and reduction. The importance of the carbamoyl region 
will be investigated with elimination of the carbonyl and nitrogen of the carbamoyl 
group. Additionally, alkylation of the secondary nitrogen will be explored. These 
structure-activity investigations ought to then elucidate the structural requirements for 
alcohol dehydrogenase inhibition.  
 
Synthesized inhibitors will be screened as inhibitors of horse liver ADH. Enzyme 
activity, converting aldehyde to alcohol with NADH as a co-factor, will be monitored. 
(This is the reaction direction required for fermentative metabolism in many anaerobic 
pathogens.) Successful inhibitors will be those that significantly decrease the observed 
enzyme activity monitored through a change in absorbance at 340 nm resulting from the 
conversion of the coenzyme NADH to NAD+ (Scheme 1). The assessment of a 
compound’s inhibition activity will be relative to that of the blank, which contains all 
components of the assay except the proposed inhibitor compound.  
 
Horse liver ADH was selected for all enzyme assays and modeling studies. Horse liver 
ADH is commonly used to model human ADH as it is homologous to the structure of 
human ADH at its active site. This enzyme is a eukaryotic ADH, which resembles the 
tertiary structure of many parasitic ADHs. Additionally, this enzyme is a zinc 
metalloenzyme requiring the coordination of two zinc cations for enzymatic activity30. 
The two zinc cations are tetracoordinated at the active site with two cysteines, a histidine, 
and one water molecule30. The substrates for horse liver ADH include benzaldehyde, 
acetaldehyde, ethanol, and benzyl alcohol31. Horse liver ADH also requires 
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NADH/NAD+ as a cofactor for activity. NADH binds to an NADH binding domain 
before substrate coordinates/binds, thus closing the active site to its active form30. A 
methionine residue (position 141) buried in the active site pocket of human ADH is 
known to play an essential role in substrate binding as well as binding 4-methylpyrazole, 
a known ADH inhibitor3. This methionine residue lines the substrate binding pocket near 
the docking site of the methyl group of 4-methylpyrazole3. Horse liver ADH used in this 
study lacks methionine at the substrate binding region but other hydrophobic amino acids 
line the substrate binding site which may engage in similar interactions (Valine-
52,53,58,63, Glycine-55,66, Leucine-57,61, Proline-60,62, Isoleucine-64, Alanine-65)31.   
 
The positive inhibition control compound within this study will be 4-methylpyrazole 
(Figure 1)2,5,32. This compound has previously been identified as a competitive inhibitor 
of alcohol dehydrogenases (Ki 0.013 μM for horse liver ADH) and our reported 
experimental enzymatic inhibition activity will be in relation to this this known value2. 
Enzyme assays will be performed with no pyrazoline inhibitor present as a positive 
control to ensure that the enzyme is functional under the given conditions. Additionally, 
control assays will be performed in the presence of NADH and inhibitor (without 
enzyme) to determine if there is any interaction between the pyrazoline compounds and 
NADH coenzyme that would perturb the spectrophotometric data analysis. 
 
1.2: Synthesis 
The reactions central to the synthetic efforts of this project are outlined below. The 
synthesis of 3-aryl 2-pyrazolines was required for all described herein. Substituents on 
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rings A and C were assessed in the para position for all derivatives to maximize the 
impact of the net electronic dipole of the aryl ring. The para substituent modifications 
focus upon the role of electron density within the ring (electron donating or withdrawing 
groups) rather than steric factors. Varied substituents at the meta position would likely 
target mainly inductive influences while the ortho position would likely target a 
substituent- dependent combination of electronic and steric influences. 
 
1.2.1: Modification of Ring A:  
In order to assess the role of the A ring, para substituents of varied electron 
donating or withdrawing character were synthesized and evaluated for their ADH 
inhibition (Scheme 2). Additionally, the influence of electronic and steric 
hindrance upon ADH inhibition at this pyrazoline position was assessed with a 
methyl group at this position in place of the 3-aryl group.  
 
Scheme 2. Synthesis of 3-aryl 2-pyrazoline. Modifications of ring A including 
para substituents.  
 
1.2.2: Modification of Ring B:  
In order to assess the role of ring B, the pyrazoline ring, it will be either reduced 
or oxidized (Scheme 3 and Scheme 4, respectively). These modifications will 
affect most directly the electronic structure of the compounds, and minimally 
steric considerations. 
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Scheme 3. Synthetic route to oxidize 1 to form 3-(4-chlorophenyl)-1-
(phenylthiocarbamoyl)-2-pyrazole 2. 
 
Oxidation of pyrazoline 1 to pyrazole 2 has been successfully performed and will 
be used to evaluate the effects of increased electron density at ring B (Scheme 
3)18. This transformation decreases the net dipole of the molecule and adds 
additional aromatic character to the molecule. This transformation alters proposed 
hydrogen bonding and stacking interactions the compounds may have within the 
enzyme active site.  
 
 
Scheme 4. Reduction of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide 
3 to N,3-diphenylpyrazolidine-1-carboxamide 4. 
 
Reduction of pyrazoline 3 via Superhydride (lithium triethylborohydride) to 
pyrazolidine 4 (Scheme 4) probes the effects of decreased electron density at the 
pyrazoline position. This modification also shortens the overall conjugated system 
within the molecule. This modification thus would aid in the identification of the 
essential elements of the pyrazoline moiety for enzyme binding and inhibition.  
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1.2.3: Modification of Ring C:  
In order to assess the role of ring C ring in ADH inhibition, a series of derivatives 
with para substituents of varied electron donating/withdrawing character were 
prepared (Scheme 5). Additionally, several N-propyl derivatives were synthesized 
to evaluate the importance and role aromatic character at this position may have 
upon ADH inhibition.  
 
Scheme 5. Synthesis of 1,3-diaryl carbamoyl 2-pyrazoline with varied 
substituents on the C ring.  
 
1.2.4: Modification of the carbamoyl region:  
In order to assess the role of electronics at the carbamoyl region on ADH 
inhibition, several carbamoyl and thiocarbamoyl derivatives were synthesized 
(Scheme 6). The net dipole difference between carbamoyl and thiocarbamoyl 
derivatives probes primarily the role of electronics at this position. Additionally, 
an amide derivative was prepared to probe the role of the carbamoyl group upon 
ADH inhibition (Scheme 7). Alkylation of the carbamoyl or thiocarbamoyl region 
was also investigated to understand the role of a large net dipole at this position, 
and to a lesser extent steric considerations (Scheme 8, Scheme 9).  
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Scheme 6. Synthesis of 1,3-diaryl carbamoyl/thiocarbamoyl derivatives.  
 
 
Scheme 7. Synthesis of compound 6, 1-(3-phenyl-4,5-dihydro-1H-pyrazol-1-
yl)butan-1-one. 
 
 
 
Scheme 8. Synthesis of compound 9, N-methyl-3-phenyl-N-propyl-4,5-dihydro-
1H-pyrazole-1-carboxamide. 
 
 
Scheme 9. Synthesis of compound 11, (1Z)‐1‐(methylsulfanyl)‐N‐propyl‐1‐(3‐ሺ4‐
chlorophenyl‐4,5‐dihydro-1H-pyrazol-1-yl)methanimine.  
 
1.3: AutoDock Visualization  
AutoDock modeling software will be employed in this study to visualize potential 
binding modes for 1,3-disubstituted 2-pyrazolines with the horse liver ADH crystal 
structure. AutoDock is an open source, three-dimensional modeling software that is 
commonly employed for ligand docking analysis and protein visualization33. AutoDock 
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was selected over other modeling programs because it is an open source software with 
user interface that does not require coding and it is a common method for calculating 
various protein-ligand docking interactions (where ligand may be substrate, cofactor, 
inhibitor, or activator)33. This program performs a series of Lamarckian genetic 
algorithms to determine likely binding configurations based upon approximations of 
favorable ligand docking interactions33.  
 
Scheme 10 Synthesis of compound 1, 3-(4-chlorophenyl)-1-(phenylthiocarbamoyl)-2-
pyrazoline. 
 
Compound 1 has been successfully synthesized and used for the evaluation of inhibitory 
ability of 1,3-disubstituted 2-pyrazoline against ADH (Scheme 10). This compound was 
selected for AutoDock modeling as it was the only completed compound at the time of 
modeling analysis. 
 
The protein crystal structure of horse liver ADH was utilized to mathematically compute 
one possible enzyme conformation and inhibitor binding site, based upon common 
ligand-binding interactions (PDB 1HLD) (Figure 5)31. The crystal structure of the 
synthesized pyrazoline compounds are unknown and solvent influences may further alter 
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the conformation of horse liver ADH in screening assays. This analysis is thus an 
estimate utilized to visualize potential binding sites. Experimental data will be used to 
determine modes of inhibition and to evaluate inhibitor efficiency.  
 
Figure 5. Crystal structure of horse liver ADH with NADH and benzyl alcohol bound 
(PDB 1HLD) used for all AutoDock visualization in this study31. 
 
The pyrazoline 1 structure was evaluated with AutoDock software to visualize a likely 
mode of binding to the horse liver ADH-NADH-benzyl alcohol complex (PDB 1HLD, 
Protein Data Bank ID 4XD2, the same enzyme complex proposed for kinetics assays). 
Additional studies would be required to determine the most likely binding modes for 
other synthesized compounds with the horse liver ADH crystal structure.  
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1.4: Description of Project 
The overall goal of the studies described herein has been to elucidate structural attributes 
responsible for pyrazoline-based inhibition of alcohol dehydrogenases. This aim will be 
accomplished through the synthesis of 1,3-disubstituted carbamoyl- 2-pyrazoline 
derivatives. Targeted and systematic structural modifications will be used to probe the 
pharmacophoric region of 1,3-diaryl pyrazoline carbamates by assessing enzyme activity 
in response to these structural and electronic changes. The steric and electronic influences 
of the pyrazoline structure upon bioactivity will be assessed through the systematic 
alteration of each of the three rings (Figure 4). Electronics are anticipated to play a 
significant role with the binding and coordination of these molecule with the enzyme 
complex or active site22. The thionyl and pyrazoline regions are proposed to play an 
essential role in binding efficiency due to the highly electrophilic character of the ADH 
binding domain31. Modification of the electronics and sterics at these positions ought to 
allow for the identification of essential structural components for optimal ADH binding.  
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Chapter 2: Research Methods and Procedures 
2.1: Materials and Methods 
All reagents used for this study were purchased from Sigma Aldrich or Alfa Aesar and 
were used in their commercial state without further purification. Concentrations of 
reagents used were as follows, unless otherwise indicated: hydrazine hydrate (60% 
reagent grade), absolute ethanol, and paraformaldehyde (95% reagent grade, powder). 
The derivatives were characterized using 1H NMR, 13C NMR, FT-IR spectroscopy, UV-
Vis spectroscopy, and/or melting point analysis. All NMR measurements were recorded 
using a JEOL EXQ 300 MHz FT-NMR Spectrometer. Deuterated solvents used for NMR 
were sourced from Sigma Aldrich and ampules were used for samples analyzed in dmso-
d6. All IR measurements were recorded using a Perkin Elmer Spectrum Two FT-Infrared 
Spectroscopy instrument. A BUCHI M-565 melting point instrument was used for all 
melting point analysis. Abbreviations used for common solvents and reagents include 
dimethylsulfoxide (DMSO), tetrahydrofuran (THF), dimethylformamide (DMF), 
nicotinamide adenine dinucleotide (NAD+), nicotinamide adenine dinucleotide reduced 
disodium salt (NADH), and dimethylamine (DMA).  
 
IUPAC refers to the common 2-pyrazoline structure as 4,5-dihydro-1H-pyrazole. The 
common nomenclature will be used henceforth in this study.  
 
2.1.1: Modification of Ring A:20  
All derivatives probing the influence of ring A on ADH inhibition were 
synthesized as described (Table 1, Scheme 3, Scheme 5). Phenone (83 mmol, 1 
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equiv.), dimethylamine hydrochloride (108 mmol, 1.3 equiv.), and 
paraformaldehyde (108 mmol, 1.3 equiv.), and four drops of 0.4 M hydrochloric 
acid was refluxed in a stirred solution of 13.5 mL ethanol. This solution was 
cooled after 1.5 hours and 100 mL of acetone was added. The resulting solid was 
washed and vacuum dried. A warm solution of 26.4 mL methanol and this 
product was added over 10 minutes to a solution of 5 mL hydrazine hydrate and 
2.70 mL 50% sodium hydroxide in 6.70 mL methanol. This solution was refluxed 
for 45 minutes after which the methanol was evaporated under reduced pressure 
to yield the product as an oil. This product (12.0 mmol, 1.00 equiv.) was 
dissolved in 40.0 mL dry ether with three drops of triethylamine and isocyanate 
(12.0 mmol, 1.00 equiv.). This solution was stirred for three days at room 
temperature and the resulting solid was filtered and vacuum dried.  
 
Table 1. Synthesis of derivatives with modifications of the ring A position.  
 
Compound # R Z Yield 
3 H O 42.8% 
12 H S 54.5% 
13 p-chlorophenyl O 40.0% 
14 p-methoxyphenyl O 32.0% 
15 p-tolyl O 58.0% 
16 p-fluorophenyl O 97.0% 
17 CH3 O 69.0% 
1 p-chlorophenyl S 39.0% 
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2.1.2: Modification of Ring B:18  
All derivatives probing the influence of oxidation of ring B were prepared as 
described (Scheme 11). Pyrazoline 13 (0.079 mmol, 0.025 g, 1.0 equiv.) and an 
iodine crystal (0.0373 g) was dissolved in 0.50 mL of DMSO18. This solution was 
refluxed for two hours before cooling to ambient temperature. A thick paste 
resulted with an orange-brown liquid supernatant. The liquid was decanted and 
the solid was washed twice with aqueous 10% sodium thiosulfate. The washes 
were combined with the decanted liquid. Ethanol (2 mL) was added with two 
drops of 0.60 M acetic acid resulting in the precipitation of black solid. The 
supernatant was decanted, and a small quantity of ice was added to the 
supernatant which induced immediate precipitation.  
 
 
 
Scheme 11. Oxidation of compound 1, 1,3-disubstituted thiocarbamoyl 2-
pyrazoline to compound 2, 1,3-disubstituted thiocarbamoyl pyrazole.  
 
The reduction of ring B was attempted several times without isolation of the 
desired pyrazolidine product (Scheme 12). A Schlenck flask was oven and flame 
dried and pyrazoline was desiccated. Pyrazoline (0.21 mmol, 0.08 g, 1.00 equiv.) 
and 6 mL anhydrous THF were added and three cycles of freeze-pump-thaw were 
performed (liquid nitrogen and ethanol bath). The solution was warmed to 0 °C 
and Superhydride (0.51 mmol, 0.52 mL, 2.50 equiv.) was added dropwise12. 
This solution was stirred two hours at 0 °C before quenching with 2 M NaOH (2.5 
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mL) slowly. The resulting liquid was concentrated, washed with 2 M NaOH, and 
back extracted in DCM. The organic layer was dried over magnesium sulfate and 
concentrated. Starting pyrazoline reactant was recovered as a white solid. This 
synthesis was repeated with longer reaction time (8 hours) and additional 
Superhydride equivalents, as well as warming to ambient temperature. Neither 
modification resulted in successful synthesis of this derivative. 
 
 
Scheme 12. Attempted reduction of compound 3, 1,3-disubstituted carbamoyl 2-
pyrazoline to compound 4, 1,3-disubstituted carbamoyl pyrazolidine. 
 
2.1.3: Modification of Ring C:20 
 All derivatives probing the influence of ring C upon ADH inhibition were 
synthesized as described (Table 2). Ketone (83 mmol, 1.0 equiv.), dimethylamine 
hydrochloride (108 mmol, 1.30 equiv.), and paraformaldehyde (108 mmol, 1.3 
equiv.), and four drops of 0.4M hydrochloric acid was refluxed in a stirred 
solution of 13.5 mL ethanol. This solution was cooled after 1.5 hours and 100 mL 
of acetone was added. The resulting solid was washed and vacuum dried. A warm 
solution of 26.4 mL methanol and this product was added over 10 minutes to a 
solution of 5 mL hydrazine hydrate and 2.70 mL 50% sodium hydroxide in 6.70 
mL methanol. This solution was refluxed for 45 minutes after which the methanol 
was evaporated under reduced pressure to yield the 3-aryl substituted 2-pyrazoline 
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product 5 as an oil. This product (5, 12.0 mmol, 1.00 equiv.) was dissolved in 
40.0 mL dry ether with three drops of triethylamine and isocyanate (12.0 mmol, 
1.00 equiv.). This solution was stirred for three days at room temperature and the 
resulting solid was filtered and vacuum dried.  
 
Table 2. Synthesis of derivatives with modification at the ring C position.  
 
 
Compound # R Z Yield 
18 n-propyl O 39.2% 
19 n-propyl S 6.90% 
20 4-methoxyphenyl O 80.0% 
21 4-chlorophenyl O 94.0% 
22 4-nitrophenyl O 83.2% 
 
2.1.4: Modification of the Carbamoyl Region:21,34,35 
The N- substituted 2-pyrazoline was prepared as described in the modification of 
ring A and C (Scheme 13). 3-aryl substituted 2-pyrazoline (5, 12.5 mmol, 1 
equiv.) was dissolved in 50 mL chloroform and cooled to 0°C. Triethylamine 
(12.5 mmol, 1 equiv.) was added gradually to the solution. Butyric anhydride 
(12.5 mmol, 1 equiv.) was added and the solution was stirred for three hours 
while warming to room temperature. Solid precipitate resulted, which was 
isolated via vacuum filtration and dried.  
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Scheme 13. Synthesis of amide derivative 6 for investigation of the carbamoyl 
region of N-substituted 2-pyrazolines.  
 
Alkylation of a carbamoyl derivative was also investigated (Scheme 14)21. 3-(4-
chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole-carboxamide 8 (20.0 mg, 0.075 
mmol, 1.00 equiv.), prepared previously was dissolved in 0.40 mL anhydrous 
THF, under nitrogen. Sodium hydride (60.0%) (0.23 mmol, 3.00 equiv.) was 
added to the solution and stirred one hour on ice. Methyl iodide (0.08 mmol, 1.00 
equiv.) was added to the stirring solution dropwise and stirred. The reaction was 
monitored by TLC with a 50% ethyl acetate: hexanes mobile phase. After two 
hours the solution was cooled on ice and an additional equivalent of NaH was 
added followed by an additional 1.50 equivalents of methyl iodide. After another 
four hours an additional equivalent of methyl iodide was added. After another 24 
hours stirring at room temperature under nitrogen, ice was added to the solution 
and the resulting precipitate was filtered. The resulting crude yellow oil and solid 
white precipitate was purified via gradient silica flash column chromatography 
(12-52% ethyl acetate: hexanes) to isolate 6.3 mg of an off-white solid 9, in 29% 
yield. (Recovered pyrazoline reactant, 15.6 mg).  
 
Scheme 14. Synthesis of an alkylated N-propyl carbamoyl 2-pyrazoline 
derivative.  
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Synthesis of the N- alkylated thiocarbamoyl derivative was also performed 
(Scheme 15)35. 3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole-
carbothiamide 10 (25.0 mg, 0.089 mmol, 1.00 equiv.) was dissolved in 1 mL 
DCM. This solution was chilled on ice before the gradual addition of methyl 
iodide (0.14 mL, 2.3 mmol, 25 equiv.). This stirring solution was warmed to room 
temperature and stirred at ambient temperature for 68 hours. The reaction was 
monitored by TLC with a 4:1 hexanes: ethyl acetate mobile phase. This solution 
was concentrated under reduced pressure, reconstituted in DCM, and washed with 
10% NaOH. The organic layer was dried over MgSO4, filtered, and concentrated 
to yield a crude yellow viscous oil (21.6 mg, 81% yield).  This oil was purified 
via silica flash column chromatography (4:1 hexanes: ethyl acetate) to yield 11 as 
a white solid (8.8 mg, 33% yield).  
 
 
Scheme 15. Synthesis of an alkylated N-propyl thiocarbamoyl 2-pyrazoline 
derivative 11.  
 
2.2: Enzyme Assays 
Horse liver alcohol dehydrogenase sourced from Sigma Aldrich (A9589) was used for all 
enzymatic kinetics assays. High-throughput enzyme kinetics screens were performed 
with 0.25 mM NADH (cofactor), 0.25 ߤM horse liver ADH, and 3 mM benzaldehyde 
(substrate) in 50 mM triethanolamine (TEA) buffer pH 7.2. High-throughput enzyme 
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kinetics assays were performed using a Spectro STAR Omega plate reader at 340 nm 
with UV-Transparent polystyrene 96 well plates. The plate reader was set in plate mode 
with a positioning delay of 0.2 seconds, a kinetic window of 1, 10 cycles, with 10 flashes 
per well and cycle, and a cycle time of 15 seconds. The orbital shaking frequency was set 
at 500 rpm with five seconds shaking before each cycle. The temperature of the plate 
reader was maintained at 30 °C for all readings. Each kinetics assay trial was monitored 
for a 5-minute time interval and temperature was maintained at 30 °C. A maximum of six 
wells were used per trial assay to minimize error associated with mixing time. A positive 
control and DMSO control were included for each assay trial to compare consistency 
between individual runs. Prepared NADH and ADH stock solutions were stored at 4 °C 
for long term storage (two months NADH, two weeks ADH).  
 
Several method conditions were employed for enzyme assay optimization, positive 
inhibition controls, and inhibitor trials. All assay conditions monitored the decrease in 
absorbance at 340 nm resulting from the conversion of NADH (absorbs at 340 nm) and 
NAD+ (minimal absorbance at 340 nm) cofactors accompanying the conversion of 
benzaldehyde substrate to benzyl alcohol (Scheme 16). All enzyme activity slopes 
reported are measured in units of M sec-1. 
 
Scheme 16. Conversion of benzaldehyde to benzyl alcohol performed by ADH and 
monitored in enzyme assays with decrease in absorbance at 340 nm.  
 
H
O OHNADH NAD+
Monitoring 340nm
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2.2.1: Method A  
This method was employed for high throughput enzyme screens with substrate 
added last and readings using an incubated plate reader. Plates were prepared with 
NADH, ADH, DMSO or diluted samples (1, 10, and 100ߤM final inhibitor 
concentration), and buffer at room temperature and incubated five minutes in the 
plate reader at 30 °C, with shaking every 10 seconds at 500 rpm. After incubation, 
benzaldehyde was added, mixed by pipetting, and immediately inserted for kinetic 
readings at 340 nm. The average time between benzaldehyde addition and the 
initial reading was approximately 15 seconds.  
 
2.2.2: Method B 
This method was employed for high throughput enzyme screens with cofactor 
added last and readings using an incubated plate reader. Plates were prepared with 
NADH, benzaldehyde, DMSO or diluted samples (1, 10, and 100 ߤM final 
concentration), and buffer at room temperature and incubated 5 minutes in the 
plate reader at 30 °C, with shaking every 10 seconds at 500 rpm. After incubation, 
ADH was added, mixed by pipetting, and immediately inserted for kinetic 
readings at 340 nm. The average time between ADH addition and the initial 
reading was approximately 15 seconds.  
 
2.2.3: Method C  
This method was employed for assay verification using a double beam UV-Vis 
spectrophotometer and quartz cuvettes. Following Method A described above 
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except performed using a Cary 5000 spectrophotometer with 1 cm quartz 
cuvettes. The same concentration of reagents was used, with benzaldehyde added 
post incubation at 30 °C. This instrument does not feature temperature control, so 
cuvettes were incubated in a water bath at 30 °C and ambient temperature was 
approximately 27 °C.  
 
2.2.4: Method D  
This method was employed to identify interference at the monitoring wavelength 
for assay components. Several assays were also performed using a Cary 5000 
UV-Vis-NIR spectrophotometer with 1 cm quartz cells. These assays verified that 
the enzyme initial rate was appropriately monitored under these assay conditions. 
For several trials, the same concentration of reagents was used from Method A 
and the volume was adjusted to a cuvette final volume of 600 ߤL. Additional 
trials including double substrate (i.e. 6 mM benzaldehyde) or double co-factor 
(i.e. 0.5 mM NADH) concentration were included. 
 
2.2.5: Method E 
This method was employed to identify interfering absorbencies near the 
monitoring wavelength for assay components. Wavelength scans from 280- 400 
nm were also done to determine if interactions between assay components 
influenced absorbance readings. These assays used the same reagent 
concentrations as Method A but some assay components were omitted in each 
trial. The final cuvette volume was adjusted to 600 ߤL for all combinations. All 
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trials were performed with 3 ߤL DMSO added and measurements were taken 
immediately after reagent addition using the Cary 5000 instrument at ambient 
temperature.  
 
2.2.6: Method F  
This method was employed to monitor the change in absorbance of tested 
inhibitor derivatives at different buffer pH conditions to assess any compound 
degradation at the pH employed. Trials were performed with 100 ߤM of 
compound 6 in TEA buffer ranging from pH 4.19 to 8.90. Buffer pH was adjusted 
using a Fisherbrand Accumet AB150 pH meter and the addition of 1 N 
sodium hydroxide or 1 N hydrochloric acid. Wavelength scans were recorded for 
only buffer and compound 6 from 280 to 400 nm over five minutes to monitor the 
stability of assay components at varied buffer pH. These measurements were 
recorded at room temperature using the Cary 5000 instrument and 1 cm quartz 
cuvettes.  
 
A minimum of three trials were performed for each compound or control. Reported 
slopes represent the average of all slopes from all trials at a given concentration. 
Reported remaining activity was calculated using the ratio of the average slope for each 
concentration over the average of all DMSO control runs. The average and standard 
deviation was calculated for each compound and percent remaining activity was 
calculated as the ratio between the average slope of each compound trial and the average 
of all DMSO standard runs. Outliers were determined and eliminated if they fell outside 
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of the lower 25% and upper 75% bounds of the data set determined by the first and third 
quartile calculations. Outliers were determined as those that lie outside of 1.5 times the 
inner quartile range.  
 
2.3: Ternary Complex Fluorescence Analysis 
Fluorescence spectroscopy analysis was performed on combinations of assay components 
to monitor ternary complexation between ADH and NADH with DMSO as a co-solvent. 
Previous studies identified a ternary complex for NADH bound to ADH with 
fluorescence emission at approximately 420 nm for an excitation wavelength of 328 nm 
at pH 7.236. The following combinations of assay components were analyzed for their 
fluorescence emission intensity at the concentrations used in Method A: (1) NADH, 
ADH, ADH and DMSO scanned immediately upon addition, (2) NADH and ADH 
scanned immediately upon addition, (3) NADH and ADH incubated for five minutes at 
30 °C, and (4) ADH, NADH, and DMSO incubated for five  minutes at 30 °C. 1 cm 
quartz fluorescence spectroscopy cells were used for all measurements. A Horiba 
Fluorolog 3 spectrofluorometer with FluorEssence 3.0.0 software was used for all 
fluorescence measurements. The excitation wavelength used for all scans was 328 nm 
with a slit width of 1 nm and an increment of 1 nm for a monitoring frame of 338- 550 
nm. 
 
2.4: AutoDock Docking Analysis 
ChemDraw 15.0 Professional MM2 Minimization calculations were used to determine 
the lowest energy conformation of pyrazoline 1 based upon computation of the 
 27
conformation with the fewest steric interactions based upon free rotation about sigma 
bonds. The default parameters were used for MM2 minimization in ChemDraw3D with a 
step interval of 2 fs, frame interval of 10 fs and 10,000 iterations.  AutoDock Version 
1.5.6 with AutoDock tools and an X-Quartz X11 display server was used for all analyses. 
Standard AutoGrid ligand docking analysis was performed with the system default 
parameters.  
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Chapter 3: Results  
3.1: AutoDock Docking Analysis 
ChemDraw Professional 15.0 MM2 Minimization was used to generate the lowest energy 
conformer for pyrazoline 1 which was used for docking analysis (Figure 6).  
 
 
 
Figure 6. Three-dimensional representation (right) of the lowest energy conformation of 
compound 1 (left) in AutoDock as determined by ChemDraw Professional 15.0 MM 
Minimization calculation.  
 
 Autodock software was used to visualize a possible binding site for pyrazoline 1 if it was 
to behave as a competitive inhibitor (Figure 7)33. Figure 7 illustrates a theoretical mode of 
binding for pyrazoline 1 with the horse liver ADH active site (PDB 1HLD, Protein Data 
Bank ID 4XD2, cofactor and substrate bound, assumed competitive inhibition) based 
upon the minimized steric interactions. This theoretical model was generated with the 
lowest energy conformation of 1 assuming the maximum number of rotational modes. 
Figure 7 provides a topological representation of this binding interaction and is indicative 
of a likely shallow binding interaction. A potential binding region for compound 1 is the 
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active site for the alcohol dehydrogenase, which is a highly electrophilic region with 
many hydrogen-bonding residues. The bent conformation of pyrazoline 1 overall may 
orient the thiocarbamate group to face into the active site of the horse liver ADH with 
phenyl groups facing outwards (Figure 7). These model approximations indicate a 
shallow potential binding site that is available to water, which increases the number of 
possible inhibitor conformations. 
   
       
Figure 7. AutoDock modeling of the interaction between compound 1 and horse liver 
ADH protein secondary structure, top/side view (left), top view (middle), and topological 
representation (right). 
 
The AutoDock viewing of the protein secondary structure identified a nonpolar active site 
with several hydrogen bonding residues that may interact with inhibitors (Figure 7). 
Residues at the substrate binding site include several polar residues (Serine-54 and 
Threonine-56,59), many nonpolar residues (Valine-52,53,58,63, Glycine-55,66, Leucine-
57,61, Proline-60,62, Isoleucine-64, Alanine-65), and several positively charged residues 
(Aspartic acid-49,50 and Histidine-51,67)31. 
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3.2: Initial Enzyme Assay Optimization  
Several modified assays were performed to verify that the assay was effective at 
monitoring enzyme activity within the initial rate window. In the absence of enzyme, 
benzaldehyde or NADH, a significant decrease in activity was observed (Table 3). Only 
3.24±1.35 percent remaining activity was observed when NADH was removed relative to 
the positive control containing all assay components. A greater change in absorbance 
readings (at 340 nm) was observed in the absence of enzyme or benzaldehyde (Table 3). 
This high change in absorbance in the absence of substrate or enzyme suggests auto-
reduction of the cofactor under the assay conditions. All enzyme activity slopes reported 
are measured in units of M sec-1. 
 
Table 3. Enzyme activity control assays. All assays performed according to Method C.  
 
  Slope St. Dev.  RSD Average Remaining Activity ±STD 
Positive Control -3.85E-04 4.44E-05 -0.12 100±0.00   (n=9) 
No ADH  -1.40E-04 2.01E-04 -1.44 36.3±5.22   (n=3) 
No 
Benzaldehyde  -1.73E-04 4.24E-05 -0.24 45.0±1.10   (n=3) 
No NADH  -1.25E-05 5.20E-05 -4.16 3.24±1.35   (n=8) 
 
The role of enzyme concentration was investigated, and 60.8% activity was observed 
with half enzyme concentration relative to the positive control (Table 4). This assay was 
performed to verify that enzyme concentration was rate limiting with substrate and 
cofactor in excess. This ensures that the assay exists under steady state conditions with 
the concentrations of substrate and cofactor changing negligibly. This drives the 
equilibrium to position in the desired direction, ensuring that the enzyme initial rate is 
being monitored. An increase in activity was observed with double the enzyme 
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concentration relative to the positive control (Table 4). The role of substrate 
concentration was also investigated and a minimal increase in activity was observed 
when the concentration of benzaldehyde was doubled (Table 5). 
 
Table 4. Enzyme concentration assays. Assay performed according to Method C, with 
indicated modification.  
 
 Enzyme Slope Percent Activity Relative to Positive Control  
Positive Control (0.25 ߤM ADH) -8.23E-04 100%   (n=1) 
Half ADH (0.13 ߤM) -5.01E-04 60.8%  (n=1) 
Double ADH (0.5 ߤM) -1.01E-03 122%   (n=1) 
 
 
Table 5. Substrate concentration assays. Assay performed according to Method C with 
indicated modification.   
 
 Substrate Slope Percent Activity Relative to Positive Control  
3 mM Benzaldehyde -6.91E-04 100%  (n=1) 
6 mM Benzaldehyde  -8.32E-04 120%   (n=1) 
 
3.3: Solvent Controls 
All derivatives were screened with DMSO as a co-solvent. DMSO is a known 
competitive ADH inhibitor with a Ki of 5 mM for horse liver ADH36. DMSO is the 
standard solvent for high throughput screens and has been used up to 3% in screens of 
acetaldehyde dehydrogenase activity37. Other suggested solvents included DMF which 
also exhibits ADH inhibition and ethanol which is a substrate for the reverse reaction and 
would influence kinetics readings38. Assays were performed to determine the optimal 
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DMSO concentration for screening. The ideal volume of DMSO resulted in a maximum 
remaining enzyme activity and minimal dispensing error. The greatest volume of DMSO 
having the minimal impact upon ADH enzymatic activity was 3 ߤL with 34.6% 
remaining activity relative to the positive control without DMSO (Figure 8). This volume 
of DMSO was used for all DMSO standard controls and derivative screenings. Stock 
solutions were adjusted to maintain the same volume of DMSO in all assay trials for 
reduced error associated with dispensing/ mixing. Significant inhibition was observed 
upon the addition of DMSO likely resulting from inhibition of the enzyme by the solvent 
as DMSO is a known ADH inhibitor36. Smaller volumes of DMSO exhibited similar 
activity and were associated with pipet delivery error. 
 
Figure 8. Percent remaining ADH activity with DMSO added to enzyme assay 
conditions (Method C).   
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3.4: Reagent Stability Assays  
The change in absorbance over time was measured for various combinations of assay 
components to ensure that non-enzyme interactions are not contributing to measured 
activity monitored at 340 nm (Figure 9). An increase in absorbance was observed for 
enzyme and NADH over time in the absence of substrate. A decrease in absorbance was 
recorded for all other combinations including the positive control, which exhibited a large 
drop in absorbance within 70 seconds (Figure 9). This suggests that the positive control 
had the greatest decrease in absorbance at this wavelength. Other assay components do 
influence measurements at this wavelength and these influences ought to be considered in 
the calculation of enzyme activity within the screen assays.  
Figure 9. Enzymatic assays monitoring the change in absorbance over time at 340 nm for 
varied combinations of assay components including ADH (Horse liver) and DMSO. 
Compound 12 at 100 ߤM, in pH 7.21 TEA buffer was assessed (with 3 ߤL DMSO for 
combinations without 100 ߤM compound 12). Assays performed according to Method C 
with the indicated modifications.  
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The stability of these compounds at pH 7.21 (assayed pH) was of concern due to the lack 
of dose dependence observed (1, 10, 100 ߤM). One of the derivatives (compound 12, N-
3-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide), was examined at 100 ߤM in 
TEA buffer. The pH was varied from 4.19 to 8.90 while monitoring any change in 
absorbance at 340 nm (Figure 10). This compound was selected and screened at this 
concentration as an example of the 1,3-disubstituted 2-pyrazoline carboxamide 
derivatives. Further studies would be required to determine the effects of pH upon other 
derivatives. The slopes of the line of best fit for each of these conditions did not vary 
greatly but the slope of the highest magnitude was observed at pH 5.71 (Table 6). This 
suggests that there is not a significant decomposition of this or other screened 
compounds. As some absorbance was observed across all pHs, this compound specific 
absorbance must be accounted for in the background readings of the assay.  
 
Figure 10. Change in absorbance at 340 nm for 100 ߤM compound 12 in TEA buffer 
adjusted to pH ranging from 4.19 to 8.90. Assays were prepared according to Method C 
with buffer pH adjusted as indicated. 
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Table 6. Slope of the best fit line for the change in absorbance at 340 nm over time of 
100 ߤM compound 12 in TEA buffer, adjusted pH to range from 4.19 to 8.90. 
TEA Buffer pH Slope 
4.19 -2.87E-05 
5.71 -3.60E-05 
7.21 -2.61E-05 
8.90 -2.43E-05 
Average -2.88E-05 
St. Dev. 5.15E-06 
 
3.5: Positive Inhibition Control 
4-Methylpyrazole was employed as the positive inhibition control compound for this 
assay. DMSO was used as a solvent for 4-methylpyrazole and percent inhibition values 
were calculated relative to the average of all DMSO standard trials. Dose dependent 
inhibition of horse liver ADH activity was observed for Method A and B (Table 7 and 
Table 8). The sequence of addition order within this screen assay does appear to matter at 
the inhibitor concentrations employed in this study.  
 
Table 7. Average screen inhibition assay trials for 4-methylpyrazole. Assays performed 
according to Method A.  
 
   Slope St. Dev.  RSD Average Remaining Activity ±STD 
 1 ߤM  -4.04E-05 8.21E-06 -0.20 66.1±21.2%  (n=6) 
 10 ߤM  -2.33E-05 2.55E-06 -0.11 39.8±6.73%  (n=5) 
 100 ߤM  -2.08E-05 7.71E-07 -0.04 36.4±1.14%  (n=4) 
 
 
NH N
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Table 8. Average screen inhibition assay trials for 4-methylpyrazole. Assays performed 
according to Method B.  
   Slope St. Dev.  RSD Average Remaining Activity ±STD 
 1 ߤM  -7.84E-05 1.92E-05 -0.24 107±33.4%  (n=7) 
 10 ߤM  -5.46E-05 1.18E-05 -0.22 74.5±20.5%  (n=6) 
 100 ߤM  -4.88E-05 5.67E-06 -0.12 66.7±9.86%  (n=6) 
 
 
3.6: Inhibition Comparison 
For all enzyme assays, “significant inhibition” activity was (arbitrarily) defined as 80-
100% inhibitory efficiency relative to the positive inhibition control, 4-methylpyrazole 
with benzaldehyde added last (Table 7). “Moderate activity” was defined as 60-80% 
inhibitory efficiency relative to 4-methylpyrazole. “Minimal activity” was defined as 0-
60% inhibitory efficiency relative to 4-methylpyrazole. The importance of addition order 
was investigated with either benzaldehyde (Method A) or enzyme added after incubation 
(Method B) for 5 minutes. The most consistent results were identified with benzaldehyde 
added after incubation. All compounds were screened with benzaldehyde added last but 
the data for several compounds with enzyme added last are also included for comparison. 
 
3.6.1: Modification of the carbamoyl region 
The 1,3-diaryl pyrazoline base structure (compound 3, N,3-diphenyl-4,5-dihydro-1H-
pyrazole-1-carboxamide) exhibited the highest ADH inhibition at 10 ߤM (Method A, 
Table 9). No significant inhibition was observed for this compound with enzyme added 
after incubation and minimal increase in enzyme activity was observed relative to the 
average of all DMSO controls. Modification of the carbamoyl of the base structure to a 
NH N
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thiocarbamoyl functional group (compound 12) resulted in no significant enzyme 
inhibition at any of the screened concentrations. Modification of the carbamoyl region of 
the pyrazoline base structure to an amide functional group (compound 6) resulted in no 
significant ADH inhibition for neither Method A nor B (Table 9 and Table 10). No 
significant inhibition was observed in response to changes in addition order for 
compound 3 or 6. Alkylation of the nitrogen of the carbamoyl region for a 3-p-
chlorophenyl-N-propyl-carbamoyl 2-pyrazoline derivative (compound 9) resulted in poor 
ADH inhibition for all concentrations screened and no dose dependent inhibition was 
measured. Alkylation of the sulfur of a 3-p-chlorophenyl-N-propyl-thiocarbamoyl 2-
pyrazoline derivative (compound 11) resulted in significant inhibition at all 
concentrations screened and dose dependent inhibition was measured.  
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Table 9. Average screen inhibition assay trials for compounds (3, 6, 9, 11, and 12) 
synthesized to probe role of carbamoyl moiety for ADH inhibition by 1,3-disubstituted 
carbamoyl 2-pyrazolines. Assays performed according to Method A.   
Compound  Slope St. Dev. RSD Average Remaining Activity ±STD 
3 1 ߤM  -6.86E-05 1.55E-05 -0.23 119±29.6%  (n=6) 
10 ߤM  -5.03E-05 1.31E-05 -0.26 85.6±31.6%  (n=6) 
100 ߤM -7.50E-05 1.78E-05 -0.24 131±25.1%  (n=6) 
6 1 ߤM  -5.67E-05 5.79E-06 -0.10 98.6±10.1%  (n=6) 
 10 ߤM  -6.30E-05 2.69E-06 -0.04 110±4.68%  (n=4) 
 
100 ߤM -6.62E-05 9.65E-06 -0.15 115±16.8%  (n=6) 
9 
1 ߤM  -6.17E-05 1.76E-06 -0.28 107±30.7%  (n=4) 
 10 ߤM  -4.89E-05 7.79E-06 -0.16 85.1±13.6%  (n=4) 
 
100 ߤM -9.18E-05 3.14E-05 -0.34 159±54.6%  (n=2) 
11 1 ߤM  -3.46E-05 2.96E-05 -0.85 60.2±51.5%  (n=4) 
 10 ߤM  -3.43E-05 9.27E-06 -0.27 59.7±16.1%  (n=4) 
 
100 ߤM -2.57E-05 1.05E-05 -0.47 44.8±18.2%  (n=4) 
12 
1 ߤM  -5.41E-05 6.87E-06 -0.13 83.0±17.1%  (n=3) 
 10 ߤM  -6.56E-05 2.07E-05 -0.32 108±36.0%  (n=6) 
 
100 ߤM -6.24E-05 3.36E-05 -0.54 330±18.5%  (n=4) 
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Table 10. Screen inhibition assay trials for compounds (3 and 6) synthesized to probe 
role of the carbamoyl moiety for ADH inhibition by 1,3-disubstituted carbamoyl 2-
pyrazolines. Assays performed according to Method B.   
Compound  Slope St. Dev. RSD Average Remaining Activity ±STD 
3 
 1 ߤM  -7.06E-05 4.76E-06 -0.07 96.4±8.29%  (n=3)  
10 ߤM  -7.78E-05 7.89E-06 -0.10 106±13.7%  (n=3)   
100 ߤM -8.23E-05 1.11E-05 -0.14 112±19.4%  (n=3)  
6 1 ߤM  -7.06E-05 4.76E-06 -0.07 102±29.0%  (n=3) 
 
10 ߤM  -7.78E-05 7.89E-06 -0.10 97.4±17.5%  (n=3) 
 
 100 ߤM -8.23E-05 1.11E-05 -0.14 111±29.3%  (n=3) 
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3.6.2: Modification of Ring A 
The role of ring A in 1,3-disubstituted carbamoyl 2-pyrazoline inhibition activity was 
investigated through enzyme inhibition screening assays (Table 11). The aryl ring was 
modified to a methyl group and this derivative exhibited only minimal ADH inhibition at 
10 ߤM (compound 17). The electron donating p-methoxyphenyl group resulted in 
moderate enzyme inhibition at 1 and 10 ߤM concentrations (compound 14). A p-
methylphenyl group resulted in moderate enzyme inhibition for all concentrations 
screened (compound 15). The electron withdrawing p-chlorophenyl group resulted in 
moderate enzyme inhibition at 1 and 10 ߤM but regained activity at 100 ߤM (compound 
13). Additionally, p-fluorophenyl substituent resulted in significant enzyme inhibition for 
all concentrations screened with the highest inhibition observed at 10 ߤM (compound 
16). The p-chlorophenyl thiocarbamoyl 2-pyrazoline derivative was also screened and 
resulted in only minimal enzyme inhibition at 1 ߤM (compound 1). None of these 
derivatives exhibited dose dependent inhibition across all three screened concentrations. 
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 Table 11. Screen inhibition assay trials for compounds (1, 13- 17) synthesized to probe 
role of ring A for ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazolines. Assays 
performed according to Method A.   
Compound  Slope St. Dev. RSD Average Remaining Activity ±STD 
1 
1 ߤM  -5.01E-05 1.48E-05 -0.29 87.1±25.7%  (n=3) 
10 ߤM  -6.36E-05 3.98E-05 -0.63 111±69.3%  (n=4) 
100 ߤM -7.94E-05 8.05E-06 -0.10 138±14.0%  (n=4) 
13 
1 ߤM  -3.59E-05 7.25E-06 -0.20 62.6±12.6%  (n=4) 
 10 ߤM  -4.46E-05 1.93E-05 -0.43 77.7±33.6%  (n=4) 
 
100 ߤM -6.88E-05 1.38E-06 -0.02 120±2.41%  (n=3) 
14 
1 ߤM  -4.33E-05 1.74E-05 -0.40 75.3±30.3%  (n=3) 
 10 ߤM  -3.27E-05 7.64E-06 -0.23 57.0±13.3%  (n=4) 
 
100 ߤM -5.95E-05 1.98E-05 -0.33 104±34.5%  (n=4) 
15 
1 ߤM  -3.82E-05 2.67E-05 -0.70 66.5±46.5%  (n=4) 
 
10 ߤM  -4.38E-05 1.71E-05 -0.39 76.3±29.8%  (n=4) 
 
100 ߤM -4.16E-05 9.44E-06 -0.23 72.3±16.4%  (n=3) 
16 1 ߤM  -3.95E-05 6.04E-06 -0.15 68.7±10.5%  (n=3) 
 
10 ߤM  -2.58E-05 8.63E-05 -3.34 45.0±150%  (n=4) 
 
100 ߤM -3.46E-05 1.73E-05 -0.50 60.2±30.0%  (n=4) 
17 1 ߤM  -7.41E-05 1.58E-05 -0.21 109±31.5%  (n=6) 
 10 ߤM  -4.81E-05 1.76E-05 -0.37 95.2±30.6%  (n=6) 
 
100 ߤM -6.28E-05 4.62E-06 -0.07 104±21.3%  (n=6) 
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3.6.3: Modification of ring C 
The role of the ring C moiety was also investigated through screening assays (Table 12). 
The N-propyl carbamoyl 2-pyrazoline derivative investigated exhibited no significant 
ADH inhibition at the concentrations screened (compound 18). The N-propyl 
thiocarbamoyl 2-pyrazoline derivative investigated also exhibited no significant ADH 
inhibition at the concentrations screened (compound 19).  
 
Substituents at the para position of the N-phenyl ring were introduced with substituents 
of varying electron donating or withdrawing character. None of these derivatives 
exhibited dose dependent inhibition over the screened concentrations. The electron 
donating p-methoxyphenyl group resulted in moderate enzyme inhibition at 1 and 10 ߤM 
concentrations (compound 20). The strong electron withdrawing p-nitrophenyl group 
resulted in minimal enzyme inhibition at 1 and 10 ߤM concentrations but significant 
inhibition at 100 ߤM (compound 22). A p-chlorophenyl group resulted in moderate ADH 
inhibition at all concentrations, with the highest enzyme inhibition observed at 1 ߤM 
(compound 21).  
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Table 12. Screen inhibition assay trials for compounds (18- 22) synthesized to probe  
role of ring C for ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazolines. Assays 
performed according to Method A.   
Compound  Slope St. Dev. RSD Average Remaining Activity ±STD 
18 
1 ߤM  -4.73E-05 2.61E-05 -0.55 82.4±45.5%  (n=4) 
10 ߤM  -5.63E-05 9.95E-06 -0.18 98.0±17.3%  (n=4) 
100 ߤM -5.65E-05 6.20E-06 -0.11 98.4±10.8%  (n=3) 
19 
1 ߤM  -5.41E-05 6.87E-06 -0.13 94.1±12.0%  (n=4) 
 10 ߤM  -6.56E-05 2.07E-05 -0.32 114±36.0%  (n=6) 
 
100 ߤM -6.25E-05 3.36E-05 -0.54 109±58.5%  (n=5) 
20 
1 ߤM  -3.63E-05 1.84E-05 -0.51 63.1±32.1%  (n=4) 
 
10 ߤM  -4.02E-05 9.82E-06 -0.24 70.0±17.1%  (n=4) 
 
100 ߤM -6.85E-05 5.58E-06 -0.08 119±9.7%  (n=4) 
21 1 ߤM  -1.88E-05 2.24E-05 -1.19 32.7±38.9%  (n=4) 
 
10 ߤM  -3.34E-05 1.21E-05 -0.36 58.2±21.0%  (n=4) 
 100 ߤM -3.95E-05 1.61E-05 -0.41 68.8±28.0%  (n=4) 
22 
1 ߤM  -4.62E-05 1.16E-05 -0.25 80.5±20.2%  (n=4) 
 10 ߤM  -5.53E-05 7.67E-06 -0.14 96.3±13.3%  (n=3) 
 
100 ߤM -2.51E-05 3.99E-05 -1.59 89.0±69.4%  (n=4) 
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3.7: Ternary Complex Analysis 
Florescence spectroscopy analysis was performed with various combinations of the assay 
components to monitor ternary complexation between ADH and NADH in the presence 
of DMSO. Previous studies identified increased fluorescence emission intensity at 
approximately 420 nm with NADH binding to ADH39.  An increase in emission intensity 
at 455 nm was observed for all assay component combinations investigated, except for 
ADH alone. ADH alone did not exhibit significant emission with this excitation 
wavelength and a minor peak was observed at 370 nm (Figure 11). The incubated sample 
of NADH and ADH exhibited lower fluorescence emission intensity at 455 nm relative to 
the other samples analyzed (Figure 11).  
 
  
Figure 11. Fluorescence emission scans for assay components excited at 328 nm. 
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Chapter 4: Discussion and Conclusions 
4.1: Discussion 
This study evaluated the inhibitory efficiency of 1,3-disubstituted carbamoyl 2-pyrazoline 
derivatives as horse liver alcohol dehydrogenase inhibitors. The assay used in this study 
was effective for high throughput screening of inhibitors, but further assay optimization 
would allow for more accurate activity determination. The high throughput assay 
performed allowed for rapid determination of inhibitory activity with a larger sample size 
than standard 1 cm cuvette trials would allow. However, this method introduced 
additional error with mixing and dispensing such small volumes. Further optimization of 
the assay conditions is necessary to minimize error associated with solvent influences and 
background change in absorbance at the monitoring wavelength for assay components. 
 
Positive control trials including all assay components (ADH, NADH, benzaldehyde, and 
buffer) were included with every screen to monitor experimental variation between trials. 
Minimal variation was observed for all positive controls with an average change in 
absorbance of -2.57E-04± 9.99E-05 (n=63) with a relative standard deviation of 0.38 
using Method A. These assay conditions exhibited measurable change in absorbance 
within the instrument detection limit and this method was deemed suitable for high 
throughput screens. Several modifications of assay concentrations were used to verify 
that kinetics readings fall within the initial rate for horse liver ADH (Table 3, Table 4, 
Table 5). Double enzyme concentration resulted in 122% activity relative to the positive 
control indicating that substrate was in excess at the concentration used for screening 
(Table 4). However, since this value was not directly correlated with enzyme 
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concentration, the concentrations used may be nearing the end of the enzyme kinetics 
initial rate region.  
 
This study offered an effective method for rapid screening of derivatives and approximate 
inhibitory efficiency. Optimization of the enzyme kinetics assay in response to these 
finding is necessary to decrease error associated with measurement and to validate 
inhibition results. Kinetics assays monitoring the change in absorbance of assay 
components over time at the wavelength of interest identified changes that may 
contribute to error associated with measured inhibition values (Figure 9, Table 6). A 
decrease in absorbance with enzyme and 100 ߤM compound 12 suggested possible 
metabolism of the compound as a substrate or cofactor analog (Figure 9).  
 
The addition order of assay components also influenced absorbance values with 
benzaldehyde added last exhibiting lower variation between runs. Adding enzyme last did 
not allow for incubation of the enzyme with cofactor and addition of the smaller volume 
(3 L) may have contributed to mixing and pipet dispensing error. The difference in 
activity in response to addition order suggests that time required for co-factor binding is 
important for accurately monitoring enzyme activity.   
 
Dimethylsulfoxide, DMSO, was used as a co-solvent for screening. Other suggested 
solvents include ethanol and methanol, but as these alcohol solvents closely resemble the 
substrate for the reverse reaction, an alternative solvent was necessary. DMSO is the 
standard solvent for high-throughput screenings in pharmaceutics and biotechnology but 
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there are known effects of DMSO on alcohol dehydrogenase activity40. DMSO is a 
known competitive inhibitor of ADH with a Ki of 0.005M.39 This solvent is known to 
react with the enzyme and NADH complex to form a ternary complex with fluorescent 
properties.39 A mixed solvent system may be investigated if solubility within these 
inhibition assays continues to be a challenge. The small 3 ߤL volume (2%) of DMSO was 
selected for all assays because it exhibited the highest percent remaining activity relative 
to the positive control and this volume was associated with our lowest pipet delivery error 
(Figure 8).  
 
Percent remaining activity for all derivative screens were compared to the DMSO 
standard runs to account for enzyme inhibition by the co-solvent. The significant 
inhibition of ADH activity by DMSO has been of concern due to error associated with 
monitoring a small fraction of total enzyme activity and potential conformational changes 
resulting from the co-solvent. Inhibition due to the DMSO co-solvent may result from 
conformational changes with DMSO- coordination which would alter ligand docking and 
these screens may not be representative of natural ADH activity/ inhibition. Ligand 
coordination in the presence of DMSO may influence the binding of these compounds 
and measured inhibition values41.  
 
Solubility of the screened inhibitors may cause the observed absorbance interference at 
higher screen concentrations. Several derivatives precipitated out of solution at higher 
assay concentrations (250 ߤM and 1 mM). Fine particulates not visible to the eye within 
the 10 and 100 ߤM assay wells may contribute to increased enzyme activity observed for 
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several compounds. Alternative co-solvents should be investigated to address issues with 
solubility and ADH inhibition.  
 
4-Methylpyrazole was employed as the positive inhibitor control compound for this study 
due to its demonstrated ADH inhibition2. ADH inhibition by this compound was used to 
evaluate the efficiency of synthesized derivatives as horse liver ADH inhibitors. A linear 
dose dependent response was not observed for 4-methylpyrazole trials which it 
suggestive that additional assay optimization may be required for this assay to replicate 
literature results (Table 7 and Table 8).  
 
 
 
Figure 12. Horse liver ADH inhibitors identified through high throughput inhibition 
screening assays of 1,3-disubstituted carbamoyl 2-pyrazoline derivatives.  
 
The systematic modification of electronic and steric factors surrounding the carbamoyl 2-
pyrazoline scaffold identified several effective horse liver ADH inhibitors at the 
concentrations screened. The synthesized 1,3-disubstituted carbamoyl 2-pyrazoline 
derivatives that resulted in horse liver ADH inhibition are shown in Figure 12. 
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This discussion of compound structural attributes will follow the observed ADH 
inhibition potency of the screened compounds. 
 
The compound with the greatest inhibition was compound 21, N-(4-chlorophenyl)-3-
phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide, with 32.7± 38.2% remaining activity at 
1 ߤM (Table 12). However, this ring C modification derivative was only moderately 
effective at higher concentrations and did not exhibit a dose dependent response. The 
success of this compound at a low concentration suggested that decreased electron 
density with ring C may contribute to ADH inhibition. Strong electron withdrawing or 
electron donating groups on ring C (compound 22 and 20, respectively) failed at ADH 
inhibition which suggested that the net dipole of this region may not be an important 
factor for ADH inhibition. Removal of ring C, as with 3-phenyl-N-propyl carbamoyl and 
thiocarbamoyl 2-pyrazoline derivatives (compounds 18 and 19) resulted in minimal 
inhibition at all concentrations screened (Table 12). This suggested that aromatic 
character at ring C may be an important factor for ADH inhibition.  
 
Derivatives investigating the role of the carbamoyl region of 1,3-disubstituted carbamoyl 
2-pyrazolines within ADH inhibition (Table 9) only identified successful inhibition with 
the alkylated thiocarbamoyl derivative (compound 11). This derivative exhibited 44.8± 
18.2% remaining activity at 100 ߤM. The ADH inhibition of this compound was 
comparable to that of 4-methylpyrazole at 100 ߤM (36.4± 1.14%, Table 7). The 3-
phenyl-2-pyrazoyl butanamide (compound 6), the N,3-diphenyl thiocarbamoyl 2-
pyrazoline (compound 11) and the N,3-diphenyl carbamoyl 2-pyrazoline (compound 9) 
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derivatives did not exhibit any ADH inhibition at the concentrations screened (Table 9). 
The ADH inhibition for these modifications suggested that non-polar interactions with 
the active site may be involved with ADH inhibition and the acyclic nitrogen of the 
carbamoyl group plays a minimal role within ADH inhibition.  
 
Modifications of the electronic character of ring A also exhibited significant ADH 
inhibition for several of the concentrations screened (Table 11). Many ring A 
modification derivatives provided ~60% inhibition activities at the 1 ߤM concentration 
(compounds 13,15 and 16). The most effective derivative of ring A modification 
derivatives at 1	ߤM was identified as compound 13, 3-(4-chlorophenyl)-N-phenyl-4,5-
diphenyl-1H-pyrazole-1-carboxamide. This derivative exhibited 62.6± 12.6% remaining 
activity at 1	ߤM and 77.7± 33.6% at 10	ߤM. Compound 16, 3‐(4‐fluorophenyl)‐N‐phenyl‐
4,5‐dihydro‐1H‐pyrazole-1-carboxamide, was also identified as an effective horse liver 
ADH inhibitor with 45.0± 15.0% remaining activity at 10 ߤM. The inhibitory activity of 
compound 16 was similar to that of 4-methylpyrazole at this concentration (39.8±17.0%) 
at 10ߤM (Table 7). The inhibition by ring A derivatives having electron withdrawing 
substituents suggested the importance of electronic character of this ring for ADH 
inhibition. However, an electron donating para- methoxyphenyl group (compound 14) 
also exhibited ADH inhibition with 57.0± 13.3% remaining activity at 10	ߤM (Table 18). 
Thus, the lack of change in ADH inhibition with varied ring A modifications implied 
that, other than having the aryl ring itself, its electronic properties may play a minor role 
in ADH inhibition.  
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Comparing the enzyme inhibition results from all of these structural modifications does 
not highlight an essential role of any single structural position for horse liver ADH 
inhibition. Thus, a combination of electronic and steric influences at these multiple 
positions are likely to be responsible for ADH inhibition. Thus, there was not a single 
pharmacophore with 1,3-disubstituted 2-pyrazolines and multiple factors influence their 
ADH inhibitory activity.   
 
The lack of dose dependence for all of these derivatives suggested errors with the assay, 
compound degradation/ metabolism, solubility issues, or an atypical mode of inhibition. 
The cause of the dose independent response was not identified for these derivatives. 
These results highlight the need for experimental optimization of a high- throughput 
inhibition screens for ADHs and the need to elucidate the operative mechanism of 
inhibition/ action of 1,3- disubstituted carbamoyl 2-pyrazoline compounds.  
 
The stability of compounds at the buffer pH used for screening assays was investigated 
through absorbance changes over a wide pH range (4.19- 8.90) (Figure 10). Compound 
12 exhibited the greatest absorbance at pH 5.71 at 340 nm and the lowest absorbance at 
pH 8.90 at 340 nm. Degradation may then be occurring under these extreme pH 
conditions. In order to confirm/ discredit metabolism or degradation of substituted 2-
pyrazoline derivatives at these pH conditions and under the assay conditions, NMR 
and/or GC/MS analysis may be pursued.   
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Limitations of this study included inhibition of ADH activity by DMSO, insolubility of 
derivatives at higher concentrations, and ternary complex formation. Given the inhibition 
of the target ADH enzyme by the co-solvent, only minimal enzyme activity was available 
to monitor and inhibit. Solubility challenges with pyrazoline compounds at higher 
concentrations also may introduce errors associated with absorbance measurements. 
Ternary complex formation was required for activity with the coordination of NADH co-
factor with ADH; ternary complex formation was anticipated between NADH and ADH 
as monitored by an increase in absorbance at 420 nm. Minimal ternary complex 
formation was detected under the assay conditions that included the DMSO, indicating 
that co-factor binding, or lack thereof, may be contributing to error associated with screen 
assays (Figure 11).  
 
4.2: Conclusion 
This study was aimed at identifying effective ADH inhibitors for their potential 
application as anti-parasitic and anti-bacterial agents. A series of 1,3-disubstituted 
carbamoyl 2-pyrazoline derivatives were synthesized with variable steric and electronic 
properties to investigate and identify the pharmacophore required for ADH inhibition. 
Several compounds synthesized and screened in this study exhibited moderate horse liver 
ADH inhibition, with few compounds exhibiting inhibition similar to 4-methylpyrazole. 
This study suggests that some 1,3-disubstituted 2-pyrazolines are effective horse liver 
ADH inhibitors but the mode of inhibition (competitive/ uncompetitive/ noncompetitive/ 
mixed) of these compounds remains to be determined.  
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Electronic and steric interactions at the carbamoyl position were anticipated to play a 
major role in enzyme inhibition given the performed computational modeling studies. 
Alkylation of the sulfur of the 3-chlorophenyl-N-propyl thiocarbamoyl derivative resulted 
in significant inhibition. Activity observed with the alkylated thiocarbamoyl derivative 
suggested that the exocyclic nitrogen (of the thiocarbamoyl group) does not play an 
essential role in ADH inhibition and nonpolar interactions may increase ADH inhibition. 
Derivatives with substituents at the para position on rings A and C were shown to effect 
ADH inhibition.  This study illustrated that para electron donating groups on ring A 
increased ADH inhibition. Thus, the electronics of ring A (and greater electron density 
contributing to the pyrazoline ring) contribute to ADH inhibition. Additionally, decreased 
electron density at ring C was associated with increased ADH inhibition. Overall, there 
was not a single pharmacophore identified through our described studies and multiple 
factors influence ADH inhibition by 1,3-disubstituted carbamoyl 2-pyrazoline 
compounds. The assay used to screen inhibitors must be further optimized to verify the 
activity of these compounds and to eliminate extraneous variables, including solubility, 
decomposition, or substrate analog metabolism.   
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Chapter 5: Future Studies 
5.1: Assay Optimization 
Additional studies are required to optimize the inhibition screen assay employed within 
this study. Additional trials of each inhibitor and standards would minimize error 
associated with measurement and improve accuracy. The source of positive inhibition 
values should be investigated to determine the mechanism of action behind any enzyme 
activity enhancement. The error associated with DMSO inhibition should be investigated 
and, in the event, that this error cannot be minimized another co-solvent or colorimetric 
assay should be attempted42. An alternative solvent system may also increase compound 
water solubility and decrease the observed error associated with DMSO as the co-solvent, 
avoiding ADH inhibition. A colorimetric assay could also be employed. One such as that 
monitoring the reduction of nitroblue tetrazolium (NBT) with the reduction of NADH in 
the presence of phenazine methosulphate (PMS) with the change in absorbance at 590 nm 
may offer an alternative to monitoring directly the cofactor conversion at 340 nm42. This 
method would also allow for high throughput screening of derivatives avoiding 
background absorbances of assay components.  
 
Several studies were performed investigating the role of addition order on enzyme 
activity and inhibition. Additional trials would help to minimize error and identify the 
optimal addition order. pH dependent effects were investigated for one compound, but 
studies of additional compounds would help to establish a relationship between pH and 
compound stability. Structure identification of the compounds at different pH values 
would help to determine if the derivatives are metabolized or decomposed at the assay 
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pH. Further assays and studies would be needed to determine if these pyrazoline 
derivatives behave as substrate or co-factor analogs for ADH. 
 
5.2: Mode of Action 
The mode of inhibition for these compounds remains unknown and classic Lineweaver 
Burke kinetics analysis should be used to determine the mode of inhibition for successful 
compounds. At this time, solubility of the compounds at high concentrations preclude 
such measurements. The determination of Ki and IC50 values would improve comparisons 
of compound efficiency and determine the mode of inhibition.  
 
5.3: AutoDock Modeling 
AutoDock modeling may be used for successful inhibitors to understand potential 
competitive binding interactions between the enzyme and the derivatives. Modeling with 
the crystal structure of horse liver ADH with substrate, cofactor, and DMSO bound 
(assuming competitive inhibition) would increase the accuracy of these approximations. 
The crystal structure of successful inhibitors may also allow for more appropriate 
AutoDock modeling analysis. AutoDock analysis with the crystal structure of human or 
bacterial ADH would also allow for an approximation of the binding modes of these 
compounds for different targets and applications.  
 
5.4: Additional Derivatives 
Future studies should also include the screening of additional derivatives. Several other 
compounds are of interest have yet to be synthesized that probe the pyrazole core and 
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sterics surrounding the carbamoyl position (Figure 13). A pyrazolidine derivative would 
probe the role of aromaticity and electron density at ring B in ADH inhibition. This 
reduction was attempted several times with Superhydride as a reducing agent with no 
conversion. Alternative reduction conditions will be investigated to achieve this 
transformation.  
 
 
Figure 13. Several proposed derivatives probing the pyrazole core and sterics 
surrounding the carbamoyl position. 
 
Additionally, oxidation of the pyrazoline ring to a pyrazole would probe the role of 
increased electron density at ring B in ADH inhibition. Investigation of N-phenyl and N-
propyl pyrazole derivatives would investigate the influences of aromaticity and steric 
interactions at ring C. This oxidation has been achieved for three pyrazole derivatives 
(compounds 2, 23, and 24) but time did not permit for adequate purification and high 
throughput screening to determine inhibitory activity of these derivatives.  
 
Furthermore, a 1,3-diphenyl 2-pyrazolylcarbamide derivative (26) was synthesized to 
target the role of the exocyclic nitrogen of the carbamoyl region. Additionally, a 
derivative completely lacking the carbamoyl moiety (25) would investigate the 
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importance of the carbamyl dipole. Both of the latter derivatives were synthesized but 
time did not permit for adequate purification and high throughput screening to determine 
their ADH inhibition. Investigation of this series of derivatives would identify the role of 
the pyrazoline and carbamoyl regions in ADH inhibition.  
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Supplemental Information A 
Compound 5 
 
Synthesis of 3-phenyl-4,5-dihydro-1H-pyrazole: 
Acetophenone, (9.90 mL, 83.2 mmol, 1.00 equiv.), dimethylamine hydrochloride (8.89 g, 
108 mmol, 1.30 equiv.), and paraformaldehyde (3.30 g, 108 mmol, 1.30 equiv.) and four 
drops of 0.40 M hydrochloric acid was refluxed in a stirred solution of 13.5 mL of ethanol. 
After two hours, the solution was cooled and 100 mL of acetone was added. The white 
crystalline solid was washed and dried. A warm solution of 26.4 mL methanol and 37.0 
mmol of this product was added to a solution of 5.00 mL hydrazine hydrate, and 2.70 mL 
50% sodium hydroxide in 6.70 mL methanol over 10 minutes and refluxed for 45 minutes. 
The methanol was evaporated under reduced pressure to yield 3-phenyl-4,5-dihydro-1H-
pyrazole as an oil, in 50.7% yield.  
 
Compound 7 
 
Synthesis of 3-(4-chlorophenyl)-4,5-1H-pyrazole: 
4-chloroacetophenone (2.50 g, 32.5 mmol, 1 equiv.), dimethylamine hydrochloride (2.62 
g, 32.1 mmol, 1 equiv.), paraformaldehyde (1.27 g, 42.4 mmol, 1.30 equiv.) and four drops 
of 0.40 M hydrochloric acid was refluxed in a stirring solution of 5.20 mL ethanol. After 
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two hours, the solution was cooled and 26.0 mL of acetone was added. The white 
crystalline solid was washed and dried. A warm solution of 11.0 mL methanol and 22.2 
mmol of this product was added to a solution of 2.25 mL hydrazine hydrate, and 1.11 mL 
50% sodium hydroxide in 2.70 mL methanol over 10 minutes and refluxed for 45 minutes. 
The methanol was evaporated under reduced pressure to yield 3-(4-chlorophenyl)-4,5-
dihydro-1H-pyrazole as a white solid, in 47.5% yield. 
 
Compound 27 
 
Synthesis of 3-(4-methoxyphenyl)-4,5-1H-pyrazole: 
4-chloroacetophenone (2.03 g, 13.3 mmol, 1.00 equiv.), dimethylamine hydrochloride 
(1.51 g, 17.3 mmol, 1.30 equiv.), paraformaldehyde (0.56 g, 17.3 mmol, 1.30 equiv.), and 
four drops of 0.40 M hydrochloric acid was refluxed in a stirring solution of 2.25 mL 
ethanol. After two hours, the solution was cooled and 10.0 mL of acetone was added. The 
white crystalline solid was washed and dried. A warm solution of 6.00 mL methanol and 
this dried product (1.37 g, 7.80 mmol, 1 equiv.) was added to a solution of 1.50 mL 
hydrazine hydrate, and 1 mL 50% sodium hydroxide in 2.00 mL methanol over 10 minutes 
and refluxed for 45 minutes. The methanol was evaporated under reduced pressure to yield 
3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole as a white solid, in 58.7% yield. 
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Compound 28 
 
Synthesis of 3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole: 
4-methylacetophenone (2.09 g, 14.9 mmol, 1.00 equiv.), dimethylamine hydrochloride 
(1.64 g, 19.4 mmol, 1.3 equiv.), paraformaldehyde (0.62 g, 19.4 mmol, 1.30 equiv.), and 
four drops of 0.40 M hydrochloric acid was refluxed as a stirring solution of 2.50 mL 
ethanol. After 1.5 hours, the solution was cooled and 10.0 mL of acetone was added. The 
white crystalline solid was washed and dried. A warm solution of 4.00 mL methanol and 
this dried product (0.92 g, 5.77 mmol, 1 equiv.) was added to a solution of 0.78 mL 
hydrazine hydrate and 0.40 mL 50% sodium hydroxide in 1.00 mL methanol over 10 
minutes and refluxed for 45 minutes. The methanol was evaporated under reduced pressure 
to yield 3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole as a yellow solid, in 18.5% yield. 
 
Compound 29  
 
Synthesis of 3-methyl-4,5-dihydro-1H-pyrazole:  
Methyl vinyl ketone (10.0 mL 176 mmol, , 1.00 equiv.) was added gradually to an ice-cold 
solution of hydrazine hydrate (10.0 mL, 176 mmol, 1.0 equiv.) in 10.0 mL of methanol. 
Upon addition, significant heat was generated, and the solution was maintained at 50°C for 
two hours. The methanol was evaporated under reduced pressure to yield white solid 
residue that was directed to the synthesis of compound 17 immediately.  
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Compound 30 
 
Synthesis of 3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole: 
4-fluoroacetophenone (2.85 g, 20.6 mmol, 1.00 equiv.), dimethylamine hydrochloride 
(2.26 g, 26.8 mmol, 1.33 equiv.), paraformaldehyde (0.80 g, 26.8 mmol, 1.33 equiv.) and 
four drops 0.40 M hydrochloric acid was added to a stirring solution of 3.5 mL ethanol. 
This solution was cooled after 1.5 hours and 10.0 mL acetone was added. White crystalline 
solid was washed and dried. A warm solution of 10.0 mL methanol and this product (3.07 
g, 18.7 mmol, 1.00 equiv.) was added to a solution of 2.00 mL hydrazine hydrate and 1.00 
mL 50% sodium hydroxide in 3.00 mL methanol over 10 minutes and refluxed for 45 
minutes. The methanol was evaporated under reduced pressure to yield 3-(4-fluorophenyl)-
4,5-dihydro-1H-pyrazole as a white solid residue, in 42.8% yield.  
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Screened Inhibitor Compounds 
Compound 1  
 
Synthesis of 3-(4-chlorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide:  
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (1.91 g, 10.5 mmol, 1.00 equiv.) was 
dissolved in 55.0 mL anhydrous ether with two drops of triethylamine and phenyl 
isocyanate (2.51 mL, 18.5 mmol, 1.00 equiv.) phenyl isothiocyanate. This solution stirred 
1.5 hours at room temperature and the solid yellow product was filtered and dried, in 39.4% 
yield. 
 
1H NMR (300 MHz, CDCl3) δ (ppm): 9.05 (bs,1H) 7.66 (dd, J= 8.6 Hz, 10.9 Hz 5H), 7.41 
(t, J= 8.3Hz, 5H), 4.47 (t, J= 9.2 Hz, 2H), 3.32 (t, J= 8.5 Hz, 2H). 
 
13C NMR (75.6 MHz, CD2Cl2) δ (ppm): 173.9, 156.0, 139.0, 136.7, 129.7, 129.1, 128.6, 
128.2, 125.4, 124.4, 48.6, 32.0. 
 
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 129.1, 128.6, 128.2, 125.4, 124.4; (-) 48.7, 
32.1. 
 
IR (neat, cm-1): 3285.4, 1595.3, 1513.6, 1449.7, 1412.8, 1349.8, 1226.1, 1086.2, 993.3, 
834.7, 761.5, 667.5. 
 
Melting Point Range: 145- 147°C 
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Compound 2 
 
Synthesis of 3-(4-chlorophenyl)-N-phenyl-1H-pyrazole-1-carbothiamide: 
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (0.025 g, 0.079 mmol, 1 equiv.) and an 
iodine crystal (0.0373 g, 0.147 mmol) was dissolved in 0.50 mL of DMSO.18 This solution 
was refluxed for 2 hours before cooling to ambient temperature. A thick paste resulted on 
the glass with an orange-brown liquid supernatant. The liquid resulting was decanted and 
the solid was washed twice with aqueous 10% sodium thiosulfate. The washes were 
combined with the decanted liquid. Ethanol (2 mL) was added with two drops of 0.60 M 
acetic acid resulting in the precipitation of black solid. The supernatant was decanted, and 
a small quantity of ice was added to the supernatant which induced immediate 
precipitation.  
This compound was not fully characterized and has not been screened for ADH inhibition. 
 
IR (neat, cm-1): 3286.0, 3038.3, 1595.5, 1514.1, 1327.0, 834.8, 761.4, 692.0. 
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Compound 3 
 
Synthesis of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (1.43 g, 9.82 mmol, 1.00 equiv.) was dissolved in 25.0 
mL anhydrous ether with three drops of triethylamine and phenyl isocyanate (1.00 mL, 
9.82 mmol, 1.00 equiv.) phenyl isocyanate. This solution stirred for three days at room 
temperature and the solid orange product was filtered and dried, in 39.0% yield. 
 
1H NMR (300 MHz, dmso-d6) δ (ppm): 8.91 (s, 1H), 8.61 (s, 6H), 7.86 (dd, J= 2.9 Hz, 8.6 
Hz, 2H), 7.62 (dd, J= 1.2Hz, 7.3 Hz, 2H), 7.44 (dd, J= 1.4 Hz, 8.8 Hz, 16H), 7.24 (t, J= 
8.5 Hz, 15H), 6.93 (tt, J= 1.2 Hz, 7.3 Hz, 8H), 3.91(t, J= 10.0 Hz, 2H), 3.28 (t, J= 10.1 Hz, 
4H, overlap with H2O impurity at 3.33 ppm). Aromatic impurity observed in spectrum. 
 
13C NMR (75.6 MHz, CD2Cl2) δ (ppm): 153.7, 152.1, 139.0, 131.6, 130.1, 129.3, 128.9, 
128.7, 128.7, 128.5, 126.7, 126.5, 126.2, 122.7, 119.3, 118.9, 44.5, 32.5. 
 
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 120.1, 128.9, 128.7, 126.7, 126.5, 126.2, 
122.7, 118.9; (-) 44.5, 32.5. 
 
IR (neat, cm-1): 3390.8, 3348.4, 2949.0, 1671.8, 1591.4, 1532.6, 1444.1, 1309.0, 746.7, 
687.0. 
 
Melting Point Range: 142.4- 153.6°C 
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Compound 6 
 
 
Synthesis of 1-(3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)butan-1-one: 
A solution of 3-phenyl-4,5-dihydro-1H-pyrazole (1.58 g, 12.5 mmol, 1 equiv.) in 50.0 mL 
chloroform was chilled on ice before the addition of triethylamine (1.26 mL, 12.5 mmol, 
1.00 equiv.) followed by butyric anhydride (2.00 mL, 12.5 mmol, 1.00 equiv.). This 
solution was warmed to room temperature and stirred for three hours. White solid 
precipitate was washed and dried, in 76.3% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (m, J= 2.6Hz, 2H), 7.43 (m, J= 2.2Hz, 3H), 
2.61 (t, J= 7.5Hz, 2H), 1.57 (m, J= 7.4Hz, 2H), 0.90 (t, J= 7.4Hz, 3H) 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 170.7, 156.5, 130.9, 130.7, 129.3, 127.0, 44.5, 
35.7, 31.8, 18.5, 14.4. 
 
IR (neat, cm-1): 3055.3, 2957.2, 1625.5, 1412.1, 1319.5, 1152.8, 1040.6, 848.4, 756.5, 
690.5, 582.8. 
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Compound 9 
 
Synthesis of 3‐(4‐chlorophenyl)‐N‐methyl‐N‐propyl‐4,5‐dihydro‐1H‐pyrazole‐1‐
carboxamide: 
3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole-carboxamide 8 (0.020 g, 0.08 
mmol, 1.00 equiv.) was dissolved in 0.40 mL THF, anhydrous under nitrogen. Sodium 
hydride (60%) (0.010 g, 0.23 mmol, 3.00 equiv.) was added to the solution and stirred 
one hour on ice. Methyl iodide (10.0 ߤL, 0.080 mmol, 1.00 equiv.) was added to the 
stirring solution dropwise and stirred. The reaction was monitored by TLC with a 50.% 
ethyl acetate: hexanes mobile phase. After two hours the solution was cooled on ice and 
an additional equivalent of NaH was added followed by an additional 1.50 equivalents 
(15.0 ߤL) of methyl iodide. After another four hours an additional equivalent of methyl 
iodide (10.0 ߤL) was added. After another 24 hours stirring at room temperature under 
nitrogen, ice was added to the solution and the resulting precipitate was filtered. The 
resulting yellow oil and solid white precipitate was isolated as an off-white solid (6.3 mg, 
29% yield) following purification (12-52% ethyl acetate: hexanes, silica gel column 
chromatography). Recovered 15.6 mg of 3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-
pyrazole-carboxamide 8.  
 
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.58 (d, J= 8.3Hz, 2H), 7.37 (d, J= 8.5Hz, 2H), 3.96 
(t, J= 9.7Hz, 2H), 3.39 (t, J= 7.7Hz, 2H), 3.02 (t, J= 10.1Hz, 4H), 1.69 (m, J= 7.5Hz, 3H), 
0.92 (t, J= 7.5Hz, 3H). 
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13C NMR (75.6 MHz, CDCl3) δ (ppm): 151.2, 135.3, 131.0, 128.9, 127.4, 21.2. (Missing 
signals are observed in DEPT-135 spectra). 
 
DEPT-135 (75.6 MHz, CDCl3) δ (ppm): (+) 128.9, 127.4, 56.3, 36.6, 11.3; (-) 52.6, 47.3, 
30.6, 21.2. 
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Compound 11 
 
 
Synthesis of (1Z)‐1‐(methylsulfanyl)‐N‐propy1‐(3‐phenyl‐4,5‐dihydro-1H-pyrazol-1-yl) 
methanimine:  
3-(4-chlorophenyl)-N-propyl-4,5-dihydro-1H-pyrazole carbothiamide 10 (0.030 g, 0.09 
mmol, 1.00 equiv.) was dissolved in 1 mL CH2Cl2. This solution was chilled on ice before 
the gradual addition of methyl iodide (0.32 g, 2.3 mmol, 25 equiv.). This stirring solution 
was warmed to room temperature and stirred at ambient temperature for 68 hours. The 
reaction was monitored by TLC with a 4:1 hexanes: ethyl acetate mobile phase. This 
solution was concentrated under reduced pressure, reconstituted in CH2Cl2, and washed 
with 10% NaOH. The organic layer was dried over MgSO4, filtered, and concentrated to 
yield a yellow viscous oil.  This oil was purified to yield 11 as a white solid (21.6 mg, 
81%).  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.63 (d, J= 6.6Hz, 2H), 7.33 (d, J= 6.8Hz, 2H), 
3.96 (t, J= 10.2, 2H), 3.48 (t, J= 7.1, 2H), 3.08 (t, J= 10.0Hz, 2H), 2.53 (s, 3H), 1.58 (m, 
J= 7.2Hz, 3H), 0.94 (t, J= 7.4Hz, 3H) 
 
13C NMR (75.6 MHz, CDCl3) δ (ppm): 150.9, 135.0, 128.9, 127.2, 53.6, 48.4, 31.2, 25.0, 
16.9, 12.0. 
 
DEPT-135 (75.6 MHz, CDCl3) δ (ppm): (+) 128.9, 127.2, 29.5, 16.9, 12.0; (-) 53.6, 48.4, 
31.2, 25.0. 
 87
 
 
 88
  
 89
 
 
  
 90
Compound 12 
 
Synthesis of N,3-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (2.58 g, 17.6 mmol, 1.00 equiv.) was dissolved in 47 
mL anhydrous ether with three drops of triethylamine and phenyl isothiocyanate (1.00 mL, 
16.9 mmol, 1.00 equiv.) phenyl isothiocyanate. This solution stirred for 1.5 hours at room 
temperature and the solid yellow product was filtered and dried, 54.5% yield. 
 
1H NMR (300 MHz, CDCl3) δ (ppm):  9.13 (bs, 1H), 7.76 (dd, J= 2.1 Hz, 6.2 Hz, 2H), 
7.65 (d, J= 7.9 Hz, 2H), 7.46 (t, J= 1.9 Hz, 3H), 7.38 (t, J= 7.6 Hz, 2H), 7.21 (t, J= 7.9 Hz, 
1H), 4.46 (t, J= 10.3 Hz, 2H), 3.34 (t, J= 10.2 Hz, 2H). 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 157.0, 138.8, 131.0, 129.0, 128.8, 126.9, 125.7, 
124.6, 48.5, 32.2. 
 
IR (neat, cm-1): 3335.0, 3050.9, 1588.1, 1516.2, 1343.6, 760.6, 688.5. 
 
Melting Point Range: 158.4- 159.4°C 
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Compound 13  
 
Synthesis of 3-(4-chlorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (1.58 g, 9.66 mmol, 1.00 equiv.) was 
dissolved in 50.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate 
(2.11 g, 9.66 mmol, 1.00 equiv.). The solution stirred for 1.5 hours at room temperature 
and yellow crystalline solid was filtered and dried, in 40.0% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm):7.98 (bs, 1H), 7.66 (dd, J= 4.7 Hz, 2.9Hz, 2H), 7.54 
(d, J= 7.5Hz, 2H), 7.41 (dt, J= 4.7Hz, 2.0Hz, 2H), 7.32 (td, J= 6.1Hz, 2.1, 2H), 7.05 (t, J= 
7.4Hz, 1H), 4.11 (t, J= 9Hz, 2H), 3.27 (t, J= 9Hz, 2H). 
 
13C NMR (75.6 MHz, CDCl3) δ (ppm): 152.5, 152.1, 138.5, 136.2, 129.9, 129.3, 129.1, 
127.7, 123.2, 120.7, 119.2, 44.6, 32.5. 
 
IR (neat, cm-1): 3284.0, 3036.0, 1647.10, 1592.6, 1532.8, 1496.7, 1314.3, 1231.2, 741.4, 
684.6. 
 
Melting Point Range: 143- 148°C 
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Compound 14 
 
Synthesis of 3-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (1.37 g, 7.80 mmol, 1.00 equiv.) was 
dissolved in 50.0 mL dry ether with three drops of triethylamine and phenyl isocyanate 
(0.85 mL, 7.80 mmol, 1.00 equiv.). This solution stirred for two hours at room temperature 
and yellow solid product was filtered and dried, in 32.0% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 8.01 (bs, 1H), 7.68 (d, J= 9.0 Hz, 2H), 7.54 (dd, J= 
1.2 Hz, 8.7 Hz, 2H), 7.32 (tt, J= 1.2 Hz, 7.3 Hz, 2H), 7.04 (t, J= 9 Hz, 2H), 6.95 (d, J= 8.9 
Hz, 2H), 4.07 (t, J=9.9 Hz, 2H), 3.87 (s, 3H), 3.27 (t, J= 9.9 Hz, 2H). 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 161.2, 154.1, 152.1, 140.0, 129.0, 128.9, 124.6, 
122.6, 119.8, 114.5, 55.9, 45.0, 32.3. 
 
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 128.9, 122.6, 119.8, 114.5, 55.9; (-) 45.0, 
32.3 
 
IR (neat, cm-1): 3348.6, 2961.4, 1658.7, 1591.9, 1418.1, 1169.6, 878.8, 687.3, 583.7. 
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Compound 15 
 
Synthesis of N-phenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-(4-methylphenyl-4,5-dihydro-1H-pyrazole (0.92 g, 5.77 mmol, 1.00 equiv.) was 
dissolved in 40.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate 
(0.70 mL, 5.77 mmol, 1.00 equiv.). The solution stirred for two hours at room temperature 
and sand colored solid/paste was filtered and dried, in 58.0% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 8.03 (bs, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.54 (dd, J= 
1.8 Hz, J= 7.6 Hz, 2H), 7.31 (t, J=7.5 Hz, 5H, overlap with CHCl3 solvent impurity peak), 
7.05 (t, J= 8.7 Hz, 1H), 4.08 (t, J=10.5 Hz, 2H), 3.28 (t, J=10.2 Hz, 2H), 2.41 (s, 3H). 
 
13C NMR (75.6 MHz, dmso-d6)  δ (ppm): 154.3, 152.5, 140.2, 140.0, 129.6, 129.3, 129.0, 
127.3, 122.7, 119.8, 114.4, 45.1, 32.2, 21.6. 
 
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 129.7, 129.0, 127.3, 122.7, 119.8, 21.6; (-) 
45.1, 32.2. 
 
IR (neat, cm-1): 3426.2, 1665.1, 1591.0, 1497.8, 1427.1, 1237.1, 742.8, 687.0, 563.3. 
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Compound 16 
 
 
 
 
Synthesis of 3‐(4‐fluorophenyl)‐N‐phenyl‐4,5‐dihydro‐1H‐pyrazole-1-carboxamide: 
3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (2.35 g, 14.3 mmol, 1.00 equiv.) was 
dissolved in 45.0 mL anhydrous ether with three drops triethylamine and phenyl isocyanate 
(1.80 mL, 14.3 mmol, 1.00 equiv.). This solution stirred for one hour at room temperature 
and the pale-yellow solid was filtered and dried, in 97.0% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.98 (bs, 1H), 7.72 (td, J= 5.3, 2.2Hz, 2H), 7.54 (dd, 
J= 7.6, 1.0Hz, 2H), 7.32 (t, J= 8.4Hz, 2H), 7.13 (t, J= 8.4Hz, 1H), 7.05 (t, J= 7.3Hz, 1H), 
4.11 (t, J= 9.6Hz, 2H), 3.28 (t, J= 10.0Hz, 2H). 
 
13C NMR (75.6 MHz, CD2Cl2) δ (ppm): 165.5, 162.2, 152.7, 152.0, 138.9, 128.9, 128.4, 
128.0, 127.9, 122.8, 118.9, 115.9, 115.6, 44.6, 32.6. 
 
DEPT-135 (75.6 MHz, CD2Cl2)) δ (ppm): (+) 128.9, 128.5, 128.4, 122.8, 118.9, 115.9, 
115.6; (-) 44.6, 32.6. 
 
IR (neat, cm-1): 3393.9, 1664.5, 1593.8, 1534.9, 1446.6, 1223.1, 838.3, 814.2, 742.6, 685.8, 
581.5. 
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Compound 17 
 
Synthesis of 3-methyl-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-methyl-4,5-dihydro-1H-pyrazole (176 mmol, 14.8g, 2.80 equiv.) was re-dissolved in 
50.0 mL anhydrous ether. Five drops triethylamine was added with phenyl isocyanate (61.2 
mmol, 8.00 mL, 1.00 equiv.) and stirred at room temperature for 1.5 hours. The resulting 
taupe-colored solid was filtered and dried, in 69% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 9.12 (bs, 1H), 7.77 (dd, J= 4.5, 1.7Hz, 2H), 7.64 (d, 
J= 7.9Hz, 2H), 7.46 (dd, J= 1.9, 4.1Hz,  2H), 7.39 (t, J= 8.3Hz, 2H), 7.21 (t, J= 7.3Hz, 
1H), 4.47 (t, J= 10.3Hz, 2H), 3.35 (t, J= 9.7Hz, 2H) 
 
IR (neat, cm-1): 3276.7, 3050.8, 1645.6, 1592.8, 1546.0, 1439.6, 1293.2, 1230.1, 751.9, 
694.9. 
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Compound 18 
 
Synthesis of 3-phenyl-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (2.00 g, 13.7 mmol, 1.00 equiv.) was dissolved in 50.0 
mL anhydrous ether with three drops of triethylamine and propyl isocyanate (1.28 mL, 
13.7 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the 
orange prude product was purified via silica flash column with a 30- 100% ethyl acetate: 
hexanes gradient, in 39.2% yield.  
 
1H NMR (300 MHz, dmso-d6) δ (ppm): 7.68 (dd, J= 5.6, 2.4Hz, 2H), 7.40 (m, J= 6Hz, 
3H), 6.9120 (t, J= 5.9 Hz, 1 H), 4.01 (t, J= 10.6Hz, 2H), 3.17 (t, J= 10.6Hz, 2H), 3.04 (q, 
J= 6.1, 2H) 1.43 (m, J= 7.2Hz, 2H), 0.84 (t, J= 7.5Hz, 3H). 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.4, 152.9, 130.3, 130.0, 129.1, 126.8, 45.4, 
41.8, 32.0, 23.8, 11.8. 
 
IR (neat, cm-1): 3353.4, 2871.6, 1637.6, 1517.6, 1256.8, 1130.1, 858.2, 757.1, 694.5. 
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Compound 19 
 
 
 
Synthesis of 3-phenyl-N-propyl-4,5-dihydro-1H-pyrazole-1-carbothioamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (2.17 g, 14.8 mmol, 1.00 equiv.) was dissolved in 50.0 
mL anhydrous ether with 3 drops of triethylamine and propyl isocyanate (1.50 mL, 14.8 
mmol, 1.00 equiv.). This solution stirred for three days at room temperature and ice was 
added to the red liquid product. Crystals formed along the phase boundary were isolated 
and dried via vacuum filtration. Compound 19 was isolated as a crystalline solid (0.25 g, 
6.9% yield) following purification via gradient silica flash column chromatography (30- 
100% ethyl acetate: hexanes).  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (dd, J= 3.9, 2.1Hz, 2H), 7.43 (dd, J= 2.1, 2.3Hz, 
3H), 4.38 (t, J= 9.8Hz, 2H), 3.64 (q, J= 5.9, 2H), 3.26 (t, J= 9.8Hz, 2H), 1.71 (m, J= 7.3Hz, 
2H), 1.0 (t, J= 7.4Hz, 3H). 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 175.6, 156.8, 131.8, 130.8, 129.2, 127.4, 49.3, 
46.2, 31.6, 22.7, 11.8. 
 
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.8, 129.2, 127.4, 11.8; (-) 49.3, 46.2, 
31.7, 22.7. 
 
IR (neat, cm-1): 3349.1, 2966.0, 1689.5, 1589.3, 1520.0, 1385.3, 1175.1, 752.0, 687.9, 
626.9. 
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Compound 20 
 
Synthesis of N-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (1.51 g, 12.0 mmol, 1.00 equiv.) was dissolved in 40.0 
mL dry ether with three drops triethylamine and p-methoxyphenyl isocyanate (1.79 g, 12.0 
mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the 
resulting peach solid was filtered and dried, in 93.8% yield.  
 
 1H NMR (300 MHz, CDCl3) δ (ppm): 7.72 (t, J= 3.8Hz, 2H), 7.45 (dd, J= 5.4Hz, 2.2Hz, 
3H), 6.87 (dd, J= 8.7, 1.6Hz, 2H), 4.09 (t, J= 9.3Hz, 2H), 3.79 (s, 3H), 3.31 (t, J= 10.5Hz, 
2H). 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.25, 153.9, 152.8, 132.9, 132.1, 130.3, 129.1, 
127.2, 121.8, 114.2, 55.7, 45.3, 32.1. 
 
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.3, 129.1, 127.2, 121.8, 114.2, 55.7; (-) 
45.3, 32.1. 
 
IR (neat, cm-1): 3392.0, 2958.1, 1657.7, 1594.9, 1535.8, 1419.8, 1240.8, 1099.9, 1032.4, 
815.3, 688.2, 575.2. 
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Compound 21 
 
 
Synthesis of N-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (1.51g, 12.0 mmol, 1.00 equiv.) was dissolved in 40.0 
mL anhydrous ether with three drops triethylamine and 4-chlorophenyl isocyanate (1.84 g, 
12.0 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the 
peach solid product was filtered and dried, in 94.0% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 7.99 (bs, 1H), 7.67 (dd, J= 3.4, 1.9Hz, 2H), 7.53 (d, 
J= 8.9Hz, 2H), 7.41 (t,  J= 2.4Hz, 3H), 7.32 (q, J= 9Hz, 3H), 4.11 (t, J= 12Hz, 2H), 3.27 
(t, J= 9.1Hz, 2H). 
 
13C NMR (75.6 MHz, CD2Cl2) δ (ppm): 154.0, 137.7, 131.4, 130.2, 128.8, 128.7, 126.5, 
120.1, 100.0, 44.4, 32.5. 
 
DEPT-135 (75.6 MHz, CD2Cl2) δ (ppm): (+) 130.2, 128.8, 128.7, 126.5, 120.1; (-) 44.4, 
32.5. 
 
IR (neat, cm-1): 3383.0, 2887.6, 1690.7, 1590.0, 1530.9, 1339.4, 822.4, 683.2, 601.7. 
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Compound 22 
 
Synthesis of N-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide: 
3-phenyl-4,5-dihydro-1H-pyrazole (1.51 g, 12.0 mmol, 1 equiv.) was dissolved in 40.0 mL 
anhydrous ether and three drops of triethylamine with p-nitrophenyl isocyanate (1.97 g, 
12.0 mmol, 1.00 equiv.). This solution stirred for three days at room temperature and the 
resulting brown solid was filtered and dried, in 83.2% yield.  
 
1H NMR (300 MHz, CDCl3) δ (ppm): 8.22 (d, J= 9.3Hz, 2H), 7.73 (m, J= 9.0Hz, 3H), 7.47 
(t, J= 6.0Hz, 3H), 4.12 (t, J= 9.8Hz, 2H), 3.34 (t, J= 9.9Hz, 2H) 
 
13C NMR (75.6 MHz, dmso-d6) δ (ppm): 155.4, 151.7, 146.9, 141.7, 131.8, 130.7, 129.1, 
127.4, 125.3, 119.0, 45.2, 32.3. 
 
DEPT-135 (75.6 MHz, dmso-d6) δ (ppm): (+) 130.7, 129.1, 127.4, 125.3, 119.0; (-) 45.2, 
32.3. 
 
IR (neat, cm-1): 3357.7, 3069.6, 1681.5, 1596.9, 1530.2, 1490.9, 1328.4, 1235.1, 1111.5, 
1086.0, 852.6, 750.5, 690.9. 
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Compound 26 
 
Synthesis of phenyl (3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone: 
3-phenyl-4,5-dihydro-1H-pyrazole (0.92 g, 6.26 mmol, 1.00 equiv.) in 50.0 mL chloroform 
was chilled on ice before the addition of triethylamine (0.65 mL, 6.26 mmol, 1.00 equiv.) 
followed by benzoic anhydride (1.42 g, 6.26 mmol, 1.00 equiv.). This solution was warmed 
to room temperature and stirred for three hours, the resulting white solid precipitate was 
vacuum filtered and dried, in 85.4% yield. 
 
This compound was not fully characterized and has not been screened for ADH inhibition. 
 
IR (neat, cm-1): 3199.1, 3001.1, 1665.5, 1628.7, 1486.7, 1284.8, 1028.1, 868.8, 703.7. 
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Supplemental Information B 
 
Horse Liver Alcohol Dehydrogenase FASTA Sequence (1HLD)31 
Highlighted region indicates the substrate binding region of the active site. These 
residues (residues 49-67) are interacting with the substrate/positioned compound 1 as 
indicated by AutoDock analysis. Pink highlighted regions indicate charged residues. 
Green regions indicate nonpolar residues and yellow regions indicate polar residues.  
 
 >1HLD:A|PDBID|CHAIN|SEQUENCE 
STAGKVIKCKAAVLWEEKKPFSIEEVEVAPPKAHEVRIKMVATGICRSDDHVVS
GTLVTPLPVIAGHEAAGIVESIGEGV 
TTVRPGDKVIPLFTPQCGKCRVCKHPEGNFCLKNDLSMPRGTMQDGTSRFTCRG
KPIHHFLGTSTFSQYTVVDEISVAKI 
DAASPLEKVCLIGCGFSTGYGSAVKVAKVTQGSTCAVFGLGGVGLSVIMGCKAA
GAARIIGVDINKDKFAKAKEVGATEC 
VNPQDYKKPIQEVLTEMSNGGVDFSFEVIGRLDTMVTALSCCQEAYGVSVIVGV
PPDSQNLSMNPMLLLSGRTWKGAIFG 
GFKSKDSVPKLVADFMAKKFALDPLITHVLPFEKINEGFDLLRSGESIRTILTF 
 
>1HLD:B|PDBID|CHAIN|SEQUENCE 
STAGKVIKCKAAVLWEEKKPFSIEEVEVAPPKAHEVRIKMVATGICRSDDHVVS
GTLVTPLPVIAGHEAAGIVESIGEGV 
TTVRPGDKVIPLFTPQCGKCRVCKHPEGNFCLKNDLSMPRGTMQDGTSRFTCRG
KPIHHFLGTSTFSQYTVVDEISVAKI 
DAASPLEKVCLIGCGFSTGYGSAVKVAKVTQGSTCAVFGLGGVGLSVIMGCKAA
GAARIIGVDINKDKFAKAKEVGATEC 
VNPQDYKKPIQEVLTEMSNGGVDFSFEVIGRLDTMVTALSCCQEAYGVSVIVGV
PPDSQNLSMNPMLLLSGRTWKGAIFG 
GFKSKDSVPKLVADFMAKKFALDPLITHVL PFEKINEGFDLLRSGESIRTILTF 
 
